Page 21234..1020..»

Archive for the ‘Genetic Testing’ Category

Top Scenario: Direct-to-Consumer Genetic Testing Market 2020 to Witness Excellent Long-Term Growth Outlook Report by ResearchDive – The Think…

The global direct-to-consumer genetic testing market is estimated to surpass $2,565.7 million by 2027, exhibiting a CAGR of 12.5% from 2020 to 2027.

The report aims to offer a clear picture of the current scenario and future growth of the global Direct-to-Consumer Genetic Testing market. The report provides scrupulous analysis of global market by thoroughly reviewing several factors of the market such as vital segments, regional market condition, market dynamics, investment suitability, and key players operating in the market. Besides, the report delivers sharp insights into present and forthcoming trends & developments in the global market.

The report articulates the key opportunities and factors propelling the global Direct-to-Consumer Genetic Testing market growth. Also, threats and limitations that have the possibility to hamper the market growth are outlined in the report. Further, Porters five forces analysis that explains the bargaining power of suppliers and consumers, competitive landscape, and development of substitutes in the market is also sketched in the report.

For More Detail Insights, Download Sample Copy of the Report at: https://www.researchdive.com/download-sample/504

The report reveals various statistics such as predicted market size and forecast by analyzing the major factors and by assessing each segment of the global Direct-to-Consumer Genetic Testing market. Regional market analysis of these segments is also provided in the report. The report segments the global market into four main regions including Asia-Pacific, Europe, North America, and LAMEA. Moreover, these regions are sub-divided to offer an exhaustive landscape of the Direct-to-Consumer Genetic Testing market across key countries in respective regions. Furthermore, the report divulges some of the latest advances, trends, and upcoming opportunities in every region.

Furthermore, the report profiles top players active in the global Direct-to-Consumer Genetic Testing market. A comprehensive summary of 10 foremost players operating in the global market is delivered in the report to comprehend their position and footmark in the industry. The report highlights various data points such as short summary of the company, companys financial status and proceeds, chief company executives, key business strategies executed by company, initiatives undertaken & advanced developments by the company to thrust their position and grasp a significant position in the market.

RESEARCH METHODOLOGY

The research report is formed by collating different statistics and information concerning the Direct-to-Consumer Genetic Testing market. Long hours of deliberations and interviews have been performed with a group of investors and stakeholders, including upstream and downstream members. Primary research is the main part of the research efforts; however, it is reasonably supported by all-encompassing secondary research. Numerous product type literatures, company annual reports, market publications, and other such relevant documents of the leading market players have been studied, for better & broader understanding of market penetration. Furthermore, medical journals, trustworthy industry newsletters, government websites, and trade associations publications have also been evaluated for extracting vital industry insights.

Connect with Our Analyst to Contextualize Our Insights for Your Business:https://www.researchdive.com/connect-to-analyst/504

KEY MARKET BENEFITS

KEY MARKET SEGMENTS

The global Direct-to-Consumer Genetic Testing market is segmented on the basis of the following:

Global Direct-to-Consumer Genetic Testing Market By Product Type:

Global Direct-to-Consumer Genetic Testing Market By Applications:

Global Direct-to-Consumer Genetic Testing Market By Regions:

Top Leading key players stated in Global Direct-to-Consumer Genetic Testing Market report are:

Ancestry, Color Genomics, Easy DNA, FamilytreeDNA (Gene By Gene), Full Genome Corporation, Helix OpCo LLC, Identigene, Karmagenes, Living DNA, Mapmygenome, MyHeritage, Pathway genomics.

The report also summarizes other important aspects including financial performance, product portfolio, SWOT analysis, and recent strategic moves and developments of the leading players.

Contact Us:

Mr. Abhishek PaliwalResearch Dive30 Wall St. 8th Floor, New YorkNY 10005 (P)+ 91 (788) 802-9103 (India)+1 (917) 444-1262 (US) TollFree : +1 -888-961-4454Email:[emailprotected]LinkedIn:https://www.linkedin.com/company/research-diveTwitter:https://twitter.com/ResearchDiveFacebook:https://www.facebook.com/Research-DiveBlog:https://www.researchdive.com/blogFollow us on:https://covid-19-market-insights.blogspot.com

Read this article:
Top Scenario: Direct-to-Consumer Genetic Testing Market 2020 to Witness Excellent Long-Term Growth Outlook Report by ResearchDive - The Think...

Dr. Rohs on the Importance of Genetic Testing in NSCLC – OncLive

Nicholas C. Rohs, MD, discusses the importance of genetic testing in nonsmall cell lung cancer.

Nicholas C. Rohs, MD, assistant professor of medicine, hematology, and medical oncology, Icahn School of Medicine, Mount Sinai, discusses the importance of genetic testing in nonsmall cell lung cancer (NSCLC).

All patients with NSCLC, particularly those with lung adenocarcinoma, should undergo genetic testing, says Rohs.

An actionable mutation can be identified in about two-thirds of patients with lung adenocarcinoma, Rohs says.These actionable mutations play an important role in the treatment selection process. Oftentimes, these actionable mutations are somatic mutations rather than germline mutations, says Rohs.

Notably, several effective and well-tolerated oral therapiesare available for patients who harbor anEGFRmutation, Rohs adds.

Additionally, although it was believed that KRAS was an undruggable target,early responses with modified KRAS inhibitors have been observed in clinical trials.

The role of KRAS mutations has garnered significantexcitement in NSCLC, and is the focus of ongoing research efforts, Rohs concludes.

Read more here:
Dr. Rohs on the Importance of Genetic Testing in NSCLC - OncLive

Genetic Testing Can Lead to Precision Medicine Therapies for Cancer – HealthITAnalytics.com

November 02, 2020 -Broad-based genetic testing could identify inherited genetic mutations and accelerate precision medicine therapies for patients with cancer, according to a study published in JAMA Oncology.

Hereditary factors play a key role in the development of many cancers, researchers at Mayo Clinics Center for Individualized Medicine noted. Identifying genetic predispositions for certain cancers can have significant implications for treatment decisions, interventions, cancer screenings, and genetic testing for patients and close relatives.

Selecting patients for genetic testing has traditionally been based on pathologic features of the cancer, age at diagnosis, family history of cancer, and other factors named in clinical guidelines. Few studies have examined the impact of broad-based testing for gene mutations in patients with cancer compared with more traditional methods of selection.

Over the course of two years, Mayo Clinic researchers provided free genetic testing and counseling for 3,084 patients as part of their standard cancer care. The project included a wide range of cancer stages and types, such as breast, colorectal, lung, ovarian, pancreatic, bladder, and prostate cancers.

The results showed that with standard guidelines, physicians were only able to find 48 percent of patients with an inherited genetic mutation.

We found that 13.5 percent of patients had an inherited mutation in a gene associated with the development of their cancer, saidNiloy Jewel Samadder, MD, a Mayo Clinic gastroenterologist and hepatologist, who is the study's author.

More than half of the patients who developed cancer due to inherited mutations were being missed, and that has major implications for family members. Everyone has some risk of developing cancer, and in most cases the disease develops by chance. However, some people are genetically predisposed to developing certain types of cancer, such as breast or colon cancers.

When researchers examined the effects of a genetic mutation discovery, the team found that one-third of patients with the highest-risk cancer genes had a change in their medical management, including the type of surgery or chemotherapy they received.

This targeted treatment would have been lost if the patients had not received genetic testing, Samadder stated.

The results demonstrate the importance of genetic testing for all patients, and not just specific individuals.

Genetic testing is underutilized in cancer care, both for patients and for their families, often due to outdated guidelines that restrict testing to a narrow group of high-risk patients, saidRobert Nussbaum, MD,chief medical officer ofInvitae Corporation.

All cancer patients should have access to complete genetic information that can guide their care and inform their families' health.

Additionally, high-risk patients should share the heritable-cause of the disease with their relatives, which will allow family members to pursue disease care for earlier cancer management and detection.

We can help prevent cancer in their loved ones because it is genetic, and they share these cancer-causing genetic changes with their children, siblings and others in their families, Samadder said. We can target prevention strategies for those high-risk individuals and hopefully prevent cancer altogether in future generations of their family.

All blood-related family members of patients found to have a genetic mutation were offered free genetic testing. Overall, one in five of these family members underwent testing, the researchers said.

Going forward, the research team hopes to be able to incorporate the studys results into the care of all patients with cancer at Mayo Clinic. The study demonstrates the potential for broad genetic testing to accelerate the development of precision medicine therapies for cancer.

Steps are being taken to ensure all patients are offered genomic sequencing to better understand the genes that led to the development of their cancer, and how to precisely target treatment and improve survival, said Samadder.

Original post:
Genetic Testing Can Lead to Precision Medicine Therapies for Cancer - HealthITAnalytics.com

One in Eight Cancer Patients Harbors Inherited Mutation that Increases Risk of Disease Development – Clinical OMICs News

In a finding that bolsters the field of personalized medicine, a new large-scale study from the Mayo Clinic reports that one in eight cancer patients they followed had an inherited mutation that increases their risk of developing a malignancy. Further, the study showed that more than half of all patients with such mutations were being missed and therefore probably not receiving optimal treatment.

The study was carried out by scientists at Mayo Clinics Center for Individualized Medicine. They conducted genetic testing in more than 3,000 patients previously diagnosed with cancer at Mayo Clinic Cancer Center locations in Arizona, Florida, and Minnesota. Their report was published in the October 30 online edition ofJAMA Oncology. doi: 10.1001/jamaoncol.2020.6252

We found that 13.5% of patients had an inherited mutation in a gene associated with the development of their cancer, says Niloy Jewel Samadder, MD, a Mayo Clinic gastroenterologist and hepatologist, who is the studys lead author. Everyone has some risk of developing cancer, and in most cases the disease develops by chance. However, some people are genetically predisposed to developing certain types of cancer, such as breast or colon cancers.

The study confirms that nearly 10%-25% of cancer-causing mutations are inherited. It also suggests that patients with these mutations are being overlooked, when they could be candidates for targeted, or personalized, therapies drugs that act specifically against target molecules or processes that are known to cause or contribute to the development or progression of cancers.

The market for targeted cancer therapies is one of the biggest and fastest growing sectors in all of pharmaceuticals. More than a dozen such treatments are already on the market and they are often given fast-track designation as candidate drugs, which makes them particularly lucrative development projects. This market currently includes multiple drugs for both solid tumors and blood cancers, including early entrants to this market: imatinib mesylate (Gleevec), trastuzumab (Herceptin), and cetuximab (Erbitux). Findings such as this one from Mayo clinic should encourage growth and expansion of this market.

In its two-year Interrogating Cancer Etiology Using Proactive Genetic Testing (INTERCEPT) study, Mayo Clinic provided free genetic testing and counseling to 3,084 Mayo Clinic patients as part of their standard cancer care. The project, representing the largest known multicenter study of universal testing of patients with cancer, included a broad mix of cancer stages and types, including breast, colorectal, lung, ovarian, pancreatic, bladder, prostate and endometrial cancers.

The researchers were surprised to find that the standard guidelines physicians relied on to determine which patients with cancer should undergo genetic testing only identified 48% of the patients with an inherited genetic mutation.

More than half of the patients who developed cancer due to inherited mutations were being missed, and that has major implications for family members, Samadder says. Everyone has some risk of developing cancer, and in most cases the disease develops by chance. However, some people are genetically predisposed to developing certain types of cancer, such as breast or colon cancers.

During the study, the researchers found that one-third of the patients with the highest-risk cancer genes had a change in their medical management when a mutation was discovered. That change could include the type of surgery or chemotherapy they received.

This targeted treatment would have been lost if the patients had not received genetic testing, Samadder emphasizes.

Genetic testing is underutilized in cancer care, both for patients and for their families, often due to outdated guidelines that restrict testing to a narrow group of high-risk patients, says Robert Nussbaum, MD, chief medical officer of Invitae Corporation. All cancer patients should have access to complete genetic information that can guide their care and inform their families health. Nussbaum was a contributing author on the study.

Besides helping to guide optimal treatment for current patients, testing for these mutations can also benefit family members by encouraging them to undergo early detection testing and to get proper treatment if they also develop malignancies.

We can help prevent cancer in their loved ones because it is genetic, and they share these cancer-causing genetic changes with their children, siblings and others in their families, Samadder explains. We can target prevention strategies for those high-risk individuals and hopefully prevent cancer altogether in future generations of their family.

In this Mayo study, all blood-related family members of patients found to have a genetic mutation were offered free genetic testing, and one in five of those people opted for testing. The researchers say that the next steps will be to incorporate the study findings into the care of all patients with cancer at Mayo Clinic.

Read the original here:
One in Eight Cancer Patients Harbors Inherited Mutation that Increases Risk of Disease Development - Clinical OMICs News

How does genetic testing influence anxiety, depression, and quality of life? A hereditary breast and ovarian cancer syndrome suspects trial – DocWire…

Background:Emotional distress associated with genetic testing for hereditary breast and ovarian cancer syndrome (HBOC) is reported to interfere with adherence to treatment and prophylactic measures and compromise quality of life.

Objectives:To determine levels of anxiety, depression, and quality of life in patients tested for pathogenic BRCA1/2 mutations and identify risk factors for the development of adverse psycho-emotional effects.

Methods:Cross-sectional observational trial involving 178 breast or ovarian cancer patients from a referral cancer hospital in Northeastern Brazil. Information was collected with the Hospital Anxiety and Depression Scale (HADS) and the World Health Organization (WHO) Quality of Life (QoL) questionnaire (WHOQOL-BREF).

Results:Patients suspected of HBOC had higher levels of anxiety than depression. The presence of (probably) pathogenic BRCA1/2 mutations did not affect levels of anxiety and depression. High schooling, history of psychiatric disease, and use of psychotropic drugs were directly associated with high anxiety. High schooling was too inversely associated with QoL as such a breast tumor. Anxiety and depression were directly correlated and both reduced significantly QoL.

Conclusion:Our results highlight the importance of psychological support and screening of risk factors for anxiety and depression and low QoL in HBOC patients at the time of testing.

Keywords:Anxiety; Breast cancer; Depression; Hereditary breast and ovarian carcinoma syndrome; Quality of life.

Read the original here:
How does genetic testing influence anxiety, depression, and quality of life? A hereditary breast and ovarian cancer syndrome suspects trial - DocWire...

Tests Show Genetic Signature of Coronavirus That Likely Infected Trump – The New York Times

President Trumps illness from a coronavirus infection last month was the most significant health crisis for a sitting president in nearly 40 years. Yet little remains known about how the virus arrived at the White House and how it spread.

The administration did not take basic steps to track the outbreak, limiting contact tracing, keeping cases a secret and cutting out the Centers for Disease Control and Prevention. The origin of the infections, a spokesman said, was unknowable.

But one standard public health technique may still shed some light: tracking the clusters genetic fingerprints.

To better understand the outbreak, The New York Times worked with prominent geneticists to determine the genetic sequence of viruses that infected two Times journalists believed to have been exposed to the coronavirus as part of their work covering the White House.

The study reveals, for the first time, the genetic sequence of the virus that may have infected Mr. Trump and dozens of others, researchers said. That genome is a crucial clue that may allow researchers to identify where the outbreak originated and whether it went on to infect others across the country.

The White House has not disclosed any effort to conduct similar genetic testing, but the studys results show that it is still possible, even weeks after positive tests. Additional sequencing could help establish the path of the virus through the White House, the role of a possible super-spreading event for Judge Amy Coney Barrett and the origin of an outbreak among the staff of Vice President Mike Pence in the last week or so.

The journalists, Michael D. Shear and Al Drago, both had significant, separate exposure to White House officials in late September, several days before they developed symptoms. They did not spend any time near each other in the weeks before their positive tests.

Mr. Shear traveled with Mr. Trump and other staff on Air Force One on Sept. 26, when Mr. Trump approached within five or six feet without a mask. Mr. Drago covered the Judge Barrett event that day and a news conference the next day near officials who were not wearing masks and later tested positive. Both journalists wore masks.

The viral genomes of the two journalists shared the same distinct pattern of mutations, the research found. Along with their exposure history, the findings suggest that they were infected as part of the broader White House outbreak, said Trevor Bedford, a geneticist at the Fred Hutchinson Cancer Research Center and the University of Washington who led the research team.

These mutations that are possessed by these viruses are quite rare in the United States, Dr. Bedford said. I am highly convinced that these viruses come from the same outbreak or cluster based on their genomes.

The study, which has been posted online but not yet peer reviewed or published in a science journal, followed academic protocols that require genetic samples to be anonymous. Mr. Shear and Mr. Drago chose to disclose their identities for this article.

Viruses constantly mutate, picking up tiny, accidental alterations to their genetic material as they reproduce. Few mutations alter how a virus functions. But by comparing patterns of mutations across many genetic sequences, scientists can construct family trees of a virus, illuminating how it spreads.

The genomes believed by these researchers to be connected to the White House outbreak do not identify a recent geographic source, in part because they are unusual. The ancestors of those viruses spread to the United States from Europe and were circulating widely across the country in April and May, but the trail goes cold after that, according to Dr. Bedford.

Geneticists said the genomes are a key piece of the puzzle that may spur future research to determine where the White House outbreak originated and where it may go next. Scientists collect and publish tens of thousands of new sequences of the coronavirus every month, and additional testing may fill in the picture.

The results show that even weeks after it was identified, the White House outbreak would be better understood by sequencing samples of more people who were infected. Swabs used in positive tests are often kept in labs for months after an initial infection, and genetic material for the coronavirus is stable if stored appropriately.

The C.D.C. routinely relies on genetic testing to help understand Covid-19 outbreaks elsewhere across the country. In a study released on Thursday, the C.D.C. cited genetic sequencing and intensive contact tracing that documented an super-spreading event at a high school retreat in Wisconsin.

But the Trump administration is not known to have conducted its own genetic analysis of people infected in the outbreak. The White House declined to respond to questions on genetic sequencing of Mr. Trump and the cluster of aides and officials who tested positive or became ill.

There is still a remote possibility, Dr. Bedford said, that a previously unseen version of the virus had been circulating undetected in Washington or Northern Virginia and infected both journalists independently from the White House cluster. More testing of the outbreak could eliminate that possibility entirely, he said.

Scientists not involved in the research who reviewed the results agreed with the conclusion that the two samples sharing rare mutations strongly suggested they are part of the same outbreak.

These genomes are probably going to be identical or nearly identical to the genome that infected the president, said Michael Worobey, head of the department of ecology and evolutionary biology at the University of Arizona.

Dr. Worobey disputed the White Houses characterization that the source of the outbreak could not be known.

A lot of things are unknowable if you make no effort to know anything about them, and this falls into this category, Dr. Worobey said. All of these things actually can be known if you make the effort and you have the transparency that scientists are desperately trying to promote as we sequence hundreds of thousands of these genomes around the world.

For months, the White House minimized the threat of the virus and eschewed basic safety precautions at official events, like wearing a mask or keeping people six feet apart.

At least 11 people who attended a Rose Garden celebration on Sept. 26 for Judge Barrett, which included an indoor event without masks, became infected with the coronavirus, including Mr. Trump. Additional genetic testing could help more clearly establish the role of that event.

Dr. Bedford and his colleagues were able to obtain a full genetic sequence for the virus that infected Mr. Shear and a partial sequence of the virus that infected Mr. Drago. Several unusual mutations matched in the two samples, sufficient evidence to determine with a very high probability that they were essentially the same genome, Dr. Bedford said.

The work was carried out by a multidisciplinary team of researchers at the University of Washington School of Medicine, the Hutchinson Center and the Brotman Baty Institute for Precision Medicine in Seattle.

The work is convincing, and it is the best way to piece together the progression of such an outbreak, said David Engelthaler, head of the infectious disease branch of the Translational Genomics Research Institute in Arizona, where he and colleagues have sequenced thousands of genomes to track the spread of the coronavirus, including devastating outbreaks at Native American reservations in the state.

Its critical no matter where we are to sequence this virus, Dr. Engelthaler said. Not just at the White House, but at the White Mountain Apache Reservation here in Arizona.

Carl Zimmer contributed reporting.

Read this article:
Tests Show Genetic Signature of Coronavirus That Likely Infected Trump - The New York Times

Rare Disease Genetic Testing Market 2020 and Forecast 2021-2027 Includes Business Impact Analysis of COVID-19 – Eurowire

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Rare Disease Genetic Testing market.

Trusted Business Insights presents an updated and Latest Study on Rare Disease Genetic Testing Market 2020-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Rare Disease Genetic Testing market during the forecast period (2020-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Rare Disease Genetic Testing Market 2020 and Forecast 2021-2027 Includes Business Impact Analysis of COVID-19

Report Overview: Rare Disease Genetic Testing Market

The global rare disease genetic testing market size was valued at USD 690.1 million in 2020 and is projected to register a Compound Annual Growth Rate (CAGR) of 8.8% from 2021 to 2027. Misdiagnosis can result in interventions that could later be considered inappropriate for the underlying disorder. Thus, the need for an accurate and timely diagnosis for rare conditions drives the demand for genetic testing. Currently, the lack of awareness pertaining to these conditions is one of the primary challenges for the market. Thus, several efforts are being undertaken to help raise awareness about various aspects of rare and ultra-rare diseases, such as the challenges pertaining to diagnosis and clinical implementation of available diagnostic approaches.

Companies like Shire Plc are engaged in supporting domestic diagnostic testing for rare disorders in certain countries and offer learning programs for healthcare experts on genetic testing. Every country has developed its registry for rare diseases that acts as a focal point of information on these conditions. Patient registries and databases play a integral role in clinical research in the field of rare diseases and help in improving healthcare planning and patient care.

A rise in the number of available registries is one of the major driving factors of the market as it enables pool data to achieve a sufficient sample size for epidemiological and/or clinical research. Furthermore, technological advancements in data collection and interpretation for clinical practice has driven the market. Companies are making efforts to ensure efficient data collection from various ethnicities, which is expected to aid in the diagnosis of thousands of patients with the same condition.

In addition, companies, such as Centogene, combine genetic testing with metabolomics and proteomics to make their data analysis process as accurate as possible. The multi-omics approach helps better understand the impact of a given mutation on the protein as well as at the metabolite level. The company has also introduced a system to simplify the sample collection process, thereby driving the adoption of genetic tests for rare disease diagnosis.

Disease Type Insights: Rare Disease Genetic Testing Market

Neurological disorders segment accounted for the largest share of 12.9% in 2019. A substantial number of commercially-approved genetic tests for neurologic conditions coupled with a high prevalence of neurological diseases has accelerated the revenue growth in this segment. Tests offered by companies are recommended by several medical institutes, such as the American Academy of Neurology, American College of Medical Genetics, and Child Neurology Society.

Furthermore, the advent of high-throughput techniques, such as exome sequencing and whole-genome sequencing, has offered lucrative opportunities for companies offering tests for diseases, such as X-ALD. Exome sequencing and whole-genome sequencing have helped in addressing complicated cases of X-ALD that present an atypical disease course.

Moreover, immunologic disorders, such as Multiple Sclerosis (MS), are among the most prevalent rare diseases. The genetic profile of MS is one of the key focus areas among researchers in this field. This is primarily to obtain relevant insights pertaining to the causes and underlying physiology of diseases, resulting in a significant share of this segment.

End-use Insights: Rare Disease Genetic Testing Market

Research laboratories & CROs captured the maximum share of 46.9% of the market in 2019. This is primarily because in a substantial number of cases, blood samples collected from patients are sent to a laboratory for testing. Laboratories offer testing based on various specialties, including molecular, chromosomal, and biochemical genetic tests. For instance, ARUP Laboratories offers testing in molecular genetics, cytogenetics, genomic microarray, and biochemical genetics.

Laboratories also offer genetic counseling services that further accelerate the uptake of services among patients. Moreover, molecular genetic testing-based laboratory testing is rapidly increasing worldwide. Genetic tests are conducted by multiple laboratories, including those that are accredited with CLIA for clinical cytogenetics, pathology, and chemistry, among other specialties. These companies are involved in expanding their test portfolio by undertaking various strategic initiatives.

For instance, in January 2020, Quest Diagnostics acquired Blueprint Genetics to enhance its expertise in genetic disorders and rare diseases. Furthermore, in June 2018, Centogene launched its diagnostic laboratory in Cambridge, Massachusetts. Such initiatives depict the growing interest of diagnostic centers in genetic testing of rare diseases, which is likely to boost segment growth.

Technology Insights: Rare Disease Genetic Testing Market

Next Generation Sequencing (NGS) accounted for the largest share of 36.6% in 2019 owing to the high usage of Whole Exome Sequencing (WES). WES is being considered a highly potential method in a case where the genetic cause of disease is unknown and is difficult to identify. WES is becoming the standard of care for patients with undiagnosed rare diseases. This is attributed to the fact that exons make up around 1.5% of an individuals genome and contain 85% of all known disease-causing mutations.

Moreover, with the declining costs of WES, the cost of genetic testing is also anticipated to reduce significantly, making the test more affordable and accessible. In addition, medical coverage for WES-based genetic tests has favored segment growth. A substantial number of private health insurance agencies cover all or part of the cost of genetic testing, post recommendation by a healthcare professional. As compared to WES, clinical Whole Genome Sequencing (WGS) has lesser demand.

However, with a continuous decrease in cost, adoption of WGS is expected to amplify. For instance, the Rady Childrens Institute for Genomic Medicine offers singleton-rapid WGS and a trio-rapid WGS at a reasonable cost. In February 2020, Dante Labs launched an initiative to offer WGS to patients with rare diseases for USD 299. The service included WGS 30X on Novaseq6000 technology, data interpretation, and personalized therapy on these diseases.

Specialty Insights: Rare Disease Genetic Testing Market

Accounting for more than 40% revenue share, molecular genetic tests led the market in 2019. Rapid technological advancements and expertise in handling & managing high throughput technologies within clinical settings have driven the revenue in this segment. Molecular genetic test methods enable investigating single genes or short lengths of DNA for the detection of mutations or variations leading to genetic disorders.

Apart from rare diseases, the method also covers testing of ultra-rare diseases, which will augment the segment growth in future. Biochemical genetic tests are expected to register the second-fastest CAGR during the forecast period owing to their efficiency to assess the activity and amount of proteins & related abnormalities for the identification of changes in the DNA that can cause a metabolic disorder.

Also, the companies are expanding their test portfolio to capitalize on the potential opportunities present in this segment. In September 2019, Blueprint Genetics collaborated with ARCHIMEDlife to launch high-quality biochemical tests for rare diseases. Such developments are anticipated to boost the revenue share of the segment in the coming years.

Regional Insights: Rare Disease Genetic Testing Market

North America accounted for the largest market share of over 47% in 2019. Factors, such as high incidence of rare disorders, a large number of rare disorders registries, and the presence of substantial numbers of R&D facilities for rare & ultra-rare diseases, and extensive investments in the diagnosis of rare disorders in the region drives the market growth. As per the National Institutes of Health (NIH), around 30 million Americans have been identified with one of 7,000+ known rare diseases. Moreover, the number of patients undergoing disease testing is expected to increase in the coming years, thereby supporting market growth.

Asia Pacific is expected to register the fastest CAGR from 2020 to 2027 due to rising awareness and target population in Asian countries. China is attempting to shift the attention of the healthcare system towards the diagnosis and treatment of rare disorders. The government in the country has included rare disease management as a public health priority in its 2030 roadmap titledHealthy China 2030. Furthermore, in June 2018, the country released its first list of rare disorders to enable the patients to find solutions effectively at their local hospitals.

Key Companies & Market Share Insights: Rare Disease Genetic Testing Market

The development of technologies, such as WES & WGS, has significantly transformed genetic testing space by offering convenient and cost-effective methods that can be conducted for a wide range of conditions across multiple clinical settings. As a result, major diagnostic companies are engaged in expanding their product portfolio that can be used to conduct tests for rare and ultra-rare conditions.

In addition, they have undertaken various initiatives, such as mergers & acquisitions, to expand their offerings and subsequently strengthen their presence in this market. For example, the acquisition of GeneDX by OPKO. The acquisition helped the latter company to expand its business in the market. Similarly, Quest strengthened its presence in the market with the acquisition of Blueprint Genetics. Another important acquisition in the market is Qiagens acquisition by Thermo Fisher.

The companies have signed an agreement in March 2020; however, it is targeted to be completed by the first quarter of 2021, as ThermoFisher Scientific is lining up finances for the USD 11.5 billion deal, with an offering worth $2.2 billion. This deal is expected to impact the life science tools and reagents market significantly. With regard to rare disorder genetic testing, Thermo Fisher Scientific is engaged in research and provides sequencing for the Osteogenesis imperfecta and Vascular Ehlers-Danlos syndrome. Some of the prominent players in the rare disease genetic testing market include:

Key companies Profiled: Rare Disease Genetic Testing Market Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub segments from 2016 to 2027. For the purpose of this study, Trusted Business Insights has segmented the global rare disease genetic testing market report on the basis of disease type, technology, specialty, end use, and region:

Disease Type Outlook (Revenue, USD Million, 2016 2027)

Technology Outlook (Revenue, USD Million, 2016 2027)

Specialty Outlook (Revenue, USD Million, 2016 2027)

End-use Outlook (Revenue, USD Million, 2016 2027)

Looking for more? Check out our repository for all available reports on Rare Disease Genetic Testing in related sectors.

Quick Read Table of Contents of this Report @ Rare Disease Genetic Testing Market 2020 and Forecast 2021-2027 Includes Business Impact Analysis of COVID-19

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Read the original:
Rare Disease Genetic Testing Market 2020 and Forecast 2021-2027 Includes Business Impact Analysis of COVID-19 - Eurowire

Direct-to-Consumer Genetic Testing Market Strategic Insights 2020 with analysis of Leading Players: 23andMe, Full Genome Corporation, Color Genomics,…

The Global Direct-to-Consumer Genetic Testing Market Report, published by Emergen Research, offers a complete assessment of the major segments of the global Direct-to-Consumer Genetic Testing market, estimating the market growth rate over the forecast timeline (2020-2027). The latest research report can be viewed as a valuable source of data and information about this particular business sphere. Our team of market experts has performed a thorough future market growth analysis and assessed the demand & supply graphs and the markets historical and future revenue generation. The report is equipped with a vivid description of the current trends of the global Direct-to-Consumer Genetic Testing market. It holds an unbiased perspective of the leading market players, intense competition, the major regions/countries, end-use industries, and a broad continuum of products available in this market. Therefore, the market intelligence report offers a 360 view of the global Direct-to-Consumer Genetic Testing industry and provides significant information pertinent to the various growth-inducing and growth-restraining factors in detail.

The latest study unravels the unfavorable impacts of the COVID-19 pandemic on the global Direct-to-Consumer Genetic Testing business sector. According to our expert team, the corona virus outbreak has had an overwhelming impact on the global economic landscape, and consequently, on this business vertical. The pandemic is expected to contribute to the potential downturn of the Direct-to-Consumer Genetic Testing industry substantially. Reportedly, this sector has been financially beleaguered since the COVID-19 lockdown restrictions were put into effect. Hence, the report highlights the financial obstacles that have slowed numerous businesses progress in this sector and disrupted the global supply chains.

Request a sample copy of the Direct-to-Consumer Genetic Testing market report @ https://www.emergenresearch.com/request-sample-form/20

Competitive Overview:

The global Direct-to-Consumer Genetic Testing market report closely studies the functioning mechanisms of the key companies participating in the global market. These companies are said to be following a slew of business expansion strategies to reinforce their financial positions in this market. As per the report, these companies account for a major portion of the overall Direct-to-Consumer Genetic Testing market share. Therefore, this section of the report emphasizes the principal strategic initiatives led by these companies, including mergers & acquisitions, joint ventures, new business deals, new product launches, collaborations, technological upgradation, and several others.

Key Market Players:

23andMe, Full Genome Corporation, Color Genomics, Genesis Healthcare, Helix OpCo LLC, FamilyTreeDNA, MyHeritage, Identigene, Pathway genomics, and Living DNA

Emergen Research has segmented the global Direct-to-Consumer Genetic Testing Market on the basis of Test Type Outlook, Distribution Channel Outlook, Application Outlook, and region:

Geographical Terrain of the Direct-to-Consumer Genetic Testing Market:

To get a discount on the report, click on the link here: @ https://www.emergenresearch.com/request-discount-form/20

Global Direct-to-Consumer Genetic Testing Market Report Table of Contents:

1.1 Research Scope

1.2 Key Direct-to-Consumer Genetic Testing market segments

1.3 Target players

1.4 Market analysis by type

1.5 Market analysis by application

1.6 Key learning objectives

1.7 Report timeline

2.1 Global Direct-to-Consumer Genetic Testing market size

2.2 Latest trends of the Direct-to-Consumer Genetic Testing market by region

2.3 Key corporate trends

3.1 Global Direct-to-Consumer Genetic Testing Market size by manufacturers

3.2 Global Direct-to-Consumer Genetic Testing Market key players

3.3 Products/solutions/services of major players

3.4 New entrants in the Direct-to-Consumer Genetic Testing market

3.5 Mergers, acquisitions, joint ventures, and expansion plans

4.1 Global Direct-to-Consumer Genetic Testing Sales by Product

4.2 Global Direct-to-Consumer Genetic Testing by Product Revenue

Request a customized copy of the report @ https://www.emergenresearch.com/request-for-customization-form/20

Key highlights of the report:

Download the full Direct-to-Consumer Genetic Testing market description @ https://www.emergenresearch.com/industry-report/direct-to-consumer-genetic-testing-market

Thank you for reading our report. For further details or to inquire about customization, please let us know, and we will offer you the report well-suited to your requirements.

About Emergen Research

At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.

Our expertise umbrellas the technological environment of all major industries, and our services help you map your actions to ensure optimal yield. Our analysts utilize their market proficiency to offer actionable insights that help our clients implement profitable strategies and optimize their return on investment. Our services are wide-ranging, right from technological environment analysis to technological profiling that highlights the existing opportunities in the market you can capitalize on to stay ahead of your competitors.

Contact Us:

Eric Lee

Corporate Sales Specialist

14671 110 Avenue, Surrey, British Columbia, V3R2A9

Emergen Research | Web: https://www.emergenresearch.com

E-mail: [emailprotected]

See the rest here:
Direct-to-Consumer Genetic Testing Market Strategic Insights 2020 with analysis of Leading Players: 23andMe, Full Genome Corporation, Color Genomics,...

Know more about- How Direct-to-consumer Genetic Testing Market is Bringing New Innovation in Upcoming Years| Myriad Genetics, MyHeritage, Gene By…

The global Direct-to-consumer Genetic Testing market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 15.0% in the forecast period of 2020 to 2025 and will expected to reach USD 2277.9 million by 2025, from USD 1301.3 million in 2019.

Direct-to-consumer Genetic Testing Market report covers the present and past market scenarios, market development patterns, and is likely to proceed with a continuing development over the forecast period. The research report on Direct-to-consumer Genetic Testing Market provides comprehensive analysis on market status and development trend, including types, applications, rising technology and region. A number of analysis tools such as SWOT analysis and Porters five forces analysis have been employed to provide an accurate understanding of this market.

Some of the key players of Direct-to-consumer Genetic Testing Market:23andMe, DNA Diagnostics Center, Myriad Genetics, MyHeritage, Gene By Gene, LabCorp, IntelliGenetics, Quest Diagnostics, Ancestry.com, Invitae, Centrillion Technology, Anglia DNA Services, Ambry Genetics, Canadian DNA Services

Get Sample Copy of this Report @https://www.reportsweb.com/inquiry&RW00013143599/sample

The Global Direct-to-consumer Genetic Testing Market research report offers an in-depth analysis of the global market, providing relevant information for the new market entrants or well-established players. Some of the key strategies employed by leading key players operating in the market and their impact analysis have been included in this research report.

Segmentation by product type:

Segmentation by application:

Get Discount for This Report @https://www.reportsweb.com/inquiry&RW00013143599/discount

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Direct-to-consumer Genetic Testing market based on product and application. It also provides market size and forecast till 2025 for overall Direct-to-consumer Genetic Testing market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America (SAM), which is later sub-segmented by respective countries and segments.

Fundamentals of Table of Content:

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered1.4 Market Analysis by Type1.5 Market by Application1.6 Study Objectives1.7 Years Considered

2 Global Growth Trends2.1 Direct-to-consumer Genetic Testing Market Size2.2 Direct-to-consumer Genetic Testing Growth Trends by Regions2.3 Industry Trends

3 Market Share by Key Players3.1 Direct-to-consumer Genetic Testing Market Size by Manufacturers3.2 Direct-to-consumer Genetic Testing Key Players Head office and Area Served3.3 Key Players Direct-to-consumer Genetic Testing Product/Solution/Service3.4 Date of Enter into Direct-to-consumer Genetic Testing Market3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product4.1 Global Direct-to-consumer Genetic Testing Sales by Product4.2 Global Direct-to-consumer Genetic Testing Revenue by Product4.3 Direct-to-consumer Genetic Testing Price by Product

5 Breakdown Data by End User5.1 Overview5.2 Global Direct-to-consumer Genetic Testing Breakdown Data by End User

Purchase This Report @https://www.reportsweb.com/buy&RW00013143599/buy/3480

About ReportsWeb:ReportsWeb.comis a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Contact Us:Call: +1-646-491-9876Email:[emailprotected]

See the rest here:
Know more about- How Direct-to-consumer Genetic Testing Market is Bringing New Innovation in Upcoming Years| Myriad Genetics, MyHeritage, Gene By...

Direct-Access Genetic Testing Market Size to receive overwhelming hike in Revenues by 2020 2027 – Eurowire

Direct-Access Genetic Testing Market Size And Forecast

Market Research Intellect has newly added an informative report on the Direct-Access Genetic Testing Market to its large volume of database. This research report sheds light on various attributes of the global market such as present scenario, historical developments and upcoming trends to understand the market clearly. This analytical market research reports a 360-degree overview of the Direct-Access Genetic Testing Market that offers massive data by analyzing the latest market trends, innovative platforms, tools, technologies and global market growth opportunities. Different global market dynamics such as market drivers, restraints, threats, risks, challenges and opportunities have been mentioned in the report. This analytical report will help both established companies and new entrants to identify the consumers demands, current market needs, market size and global competition among leading key players.

Regional outlook:

The Direct-Access Genetic Testing Market has been examined into various global regions such as North America, Latin America, Middle East, Asia-pacific, Africa and Europe based on various perspectives like type, applications, market size, etc. North America is leading the market position in Direct-Access Genetic Testing Market over the forecast period. Furthermore, Asia-Pacific region is marking and impressive growth for the Direct-Access Genetic Testing Market.

A notable feature of this innovative market research report is, it comes with detailed analysis on, impact of covid-19 on Direct-Access Genetic Testing Market growth. The viral outbreak of COVID-19 (Corona Virus) across the global regions led to a sudden pause in production and manufacturing activities in various business sectors. Moreover, rising stringent rules and regulations imposed by the government on industrial sector are also affecting the production capabilities for the Direct-Access Genetic Testing Market. Due to the disruption to the manufacturing process and push-out of global customer orders, the market is getting affected presently. We at Market Research Intellect, offer insight views on the Direct-Access Genetic Testing Market for making strategic business decisions over the forecast period.

Competitive Landscape:

A competitive landscape of the Direct-Access Genetic Testing Market has been presented by examining numerous leading companies functioning across the leading global regions. Moreover, it sheds light on various attributes such as company overview, contact information, product overview, financial overview, marketing methodologies and distribution channels.

Following key players have been profiled with the help of proven research methodologies:

Direct-Access Genetic Testing Market Segmentation:

Direct-Access Genetic Testing Market Segment by Type:

Direct-Access Genetic Testing Market Segment by Application:

Direct-Access Genetic Testing Market Segment by Global Presence:

North America Latin America Middle East Asia-Pacific Africa Europe

The report has been aggregated by using a couple of research methodologies such as primary and secondary research techniques. It helps in collecting informative pieces of professional information for deriving effective insights into the market. This informative report helps in making well informed and strategic decisions throughout the forecast period.

Key questions answered through this analytical market research report include:

What is the Direct-Access Genetic Testing Market? What are the primary factors boosting the Direct-Access Genetic Testing Market? What will be the Direct-Access Genetic Testing Market size and the growth rate over the forecast period? What are the outcomes of SWOT and Porters five forces in market growth? What are the demanding regions across the globe? What are the challenges, threats and risks faced by new entrants in the market? What are the global market growth opportunities in front of the market growth? Which factors are responsible for hampering the market growth? What are the latest trends in the market? What are the recent industry developments in Direct-Access Genetic Testing Market?

If you have any custom requirements, please let us know and we will offer you the customized report as per your requirements.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Website https://www.marketresearchintellect.com/

See the original post:
Direct-Access Genetic Testing Market Size to receive overwhelming hike in Revenues by 2020 2027 - Eurowire

Efforts to Target Actionable Alterations in Lung Cancer Abound, Emphasizing Need for Testing – OncLive

With the rise of actionable mutations in lung cancer, the role of molecular testing has become increasingly important, according to Tony S. K. Mok, MD, BMSc, FRCPC, FASCO, and as more targeted agents emerge in the treatment landscape, the results from these tests must be used to inform clinical decisions.

Molecular testing to find a targetable mutation is already an important part of our daily practice. However, the process of finding these mutations may not be easy, said Mok. I believe we have a moral obligation to give it our best try. We need to obtain the best tissue or blood sample [that we can] and then use molecular testing to [identify] whether an oncogene driver [is present] so that we can select the appropriate treatment for each patient.

In an interview with OncLive, Mok, chairman of the Department of Clinical Oncology and Li Shu Fan Professor of Clinical Oncology at The Chinese University of Hong Kong, discussed the actionable mutations that have been identified in the lung cancer space, the agents that have been developed to target them, and the importance of genetic testing to provide personalized care.

Mok: In the EGFR-mutant lung cancer space, we have 3 generations of therapies available. First-generation agents include erlotinib (Tarceva) and trametinib (Mekinist). Second-generation agents include afatinib (Gilotrif) and dacomitinib (Vizimpro). Finally, we have the third-generation agent, osimertinib. Each of these agents have their own set of special features; however, we now must determine whether there is one subgroup that may benefit more from one particular therapy than the others. For example, its understood that osimertinib may have superiority in patients who have brain metastases.

If there was an Oscar Award for the arena of lung cancer in 2020, then it would probably go to the ADAURA trial. This study was published in The New England Journal of Medicine and reported the use of osimertinib in the adjuvant setting for patients with resectable EGFR-mutant NSCLC.

The primary end point of the trial was disease-free survival (DFS) in patient with stage II/IIIa disease. There was a hazard ratio of 0.17. Now, with the DFS and impressive hazard ration, there is a reasonable chance that it may translate into an overall survival (OS) benefit.

I believe that every patient with resectable EGFR-mutant lung cancer should be informed about the study. The question of whether we should wait for OS data is debatable. However, the way I see it is, if a patient doesnt know about this [potential option], then they dont have a choice. What would happen if we do end up finding an OS benefit years later, but we had not informed our patients? This is an important study and our patients should be informed about it.

In the upcoming years, I believe that will be the focus of many efforts: the management of osimertinib (Tagrisso) resistance. As demonstrated during the 2020 ASCO Virtual Scientific Program and the 2020 ESMO Virtual Congress, there have been several exciting advancements.

For example, there is the use of bispecific antibodies that target both EGFR and MEK mutations. When [amivantamab (JNJ-61186372; JNJ-6372) was] used with lazertinib, there is a response rate of about 36%, which is encouraging for patients who have already [progressed on] osimertinib.

The other approach is to use an antibody-drug conjugate [ADC]. Another report from ESMO looked at the use of patritumab deruxtecan [U3-1402], which is an ADC that targets HER3; this agent also demonstrated a response of about 25%. I believe theres a lot of room for development when it comes to using different modalities to target patients who are resistant to osimertinib.

In terms of BRAF mutations, its quite standard to use the combination of trametinib and dabrafenib (Tafinlar) in patients with BRAF V600Epositive disease, either in the first- or second-line setting. [Its also important to remember the] resistance mechanism that has been reported [with this approach].

We have also seen exciting data in terms targeting ALK mutations. Two new compounds have been explored in phase 3 studies that turned out to be positive. For example, the CROWN study evaluated the role of first-line lorlatinib (Lorbrena), the central nervous system efficacy that we saw, and how the use of this agent compares with other second-generation TKIs.

With regard to ROS1, beyond crizotinib (Xalkori), theres entrectinib (Rozlytrek) and erlotinib. [We are examining] what the role of these agents will be in the management of ROS1-positive lung cancer.

Crizotinib was evaluated in about 50 patients who harbored ROS1 mutations, and we saw a high response rate of about 72% and a PFS of about 19 months. Stepping into the present, there are now additional studies to consider.

Lorlatinib was also able to target ROS1 and was included in the report by Benjamin Solomon, MD, of Peter MacCallum Cancer Centre, and colleagues, were also able to demonstrate a high efficacy, as well. Even after [progressing on] crizotinib, there was a response rate of over 30% [with this agent]. Entrectinib (Rozlytrek) is also used to ROS1 and has been associated with a high response rate.

BRAF V600E in a driver oncogene, which we know from melanoma. However, this could also occur in lung cancer, in about 3% of patients. Why V600E? Its because this transformation will add on to the growth signal that is actually controlled by the BRAF pathway. To adequately inhibit this [mutation, we needed] dual targeting.

As such, trametinib plus dabrafenib has been shown to be better than dabrafenib monotherapy. Now, [with this approach], there is an associated response rate of 60%, in the first- or second-line settings, and the median PFS is about 10 months. We should not miss the opportunity to identify a BRAF mutation, because patients can benefit from this inhibition.

Molecular testing has become a standard of care. The first target [that was discovered was] EGFR but, in a relatively short time, we were able to identify ALK and ROS1. As such, [those targets] have now become a part of daily practice, as well.

However, it doesn't stop there. There are also BRAF V600E and MET 14 skipping mutations. In the future, we could potentially target HER2, RET, and NTRK in this space. Instead of testing just one [mutation] at a time, we could test for all of them from the start.

There is still some debate around who should receive next-generation sequencing (NGS) early on; however, in the United States, its common for patients with lung cancer to undergo NGS from the start, before treatment initiation.

Read this article:
Efforts to Target Actionable Alterations in Lung Cancer Abound, Emphasizing Need for Testing - OncLive

First Line Sequencing Seen as a Win for Both Parents and Doctors of Infants in ICU – Clinical OMICs News

Two new studies from Rady Childrens Institute for Genomic Medicine (RCIGM) find that parents and doctors of critically ill infants view first line sequencing as beneficial, whether or not a definitive diagnosis is achieved. The studies were both part of the second Newborn Sequencing in Genomic Medicine and Public Health (NSIGHT2) study and were published in early November in The American Journal of Human Genetics.

This groundbreaking research into stakeholders experiences with sequencing in the NICU provides another justification for incorporating sequencing as standard care of critically ill infants with undiagnosed conditions. RCIGM is one of the worlds leading centers for rapid genomic sequencing of infants and children with serious undiagnosed diseases.

(Thousands of) conditions can be diagnosed using sequencing, says David Dimmock, M.D., senior medical director for RCIGM, lead author of one paper, and a contributing author on the other. However, there has been little research into how parents and clinicians of infants who have undergone sequencing view the process. The results, say the Rady researchers, were surprisingly positive.

The sequencing part of the study used the Illumina Novoseq 6000 and both whole-exome sequencing (WES) and whole-genome sequencing (WGS) were used. Results were confirmed using Sanger sequencing, chromosomal microarrays, or other methods, and were typically returned, on average, in 12 days. A total of 213 infants were enrolled, but those considered very ill were tested and excluded from the study.

In the case of babies who received genomic sequencing, we surveyed their physicians and parents and found that both groups overwhelmingly felt that genetic testing was beneficial, says Stephen Kingsmore, M.D., DSc, president & CEO of RCIGM. When results are positive, sequencing reveals the genetic variation responsible for the childs disease. But what astounded us was the high proportion of both doctors and parents who perceived that this testing had life-changing utility, even in cases when results were negative for genetic disease.

All of the cases for these two studies were from Radys own ICU, although the NSIGHT project encompasses other sites as well. This study included 201 infants who received rapid genomic sequencing. The physicians found genomic sequencing medically useful 93% (42 of 45 cases) of the time when the test was positiveor helped to make a diagnosis. When the test was negative, sequencing was also deemed useful 72% (112 of 156) of the time. According to the physicians, rapid genomic sequencing improved outcomes for 32 infants in the study. Changes in the patients management were more likely when test results were returned rapidly.

Parents also had an overwhelmingly positive view of genomic testing in the ICU setting. Of 161 parents whose children received sequencing, 97% reported that the testing was useful. Only two parents reported that testing increased their stress or confusion. Overall, in 81% of the cases, families and their clinicians agreed that genomic test results were useful. Besides seeing the testing as beneficial, parents were mostly satisfied with the process. The authors of the paper on parents responses wrote, Most parents in this study perceived being adequately informed to consent, understood their childs results, and denied regret or harm from undergoing sequencing.

As part of the study, Findings that explained the hospitalization were always returned, notes Dimmock, and actionable off-target findings were also returned if requested.

Not surprisingly, positive results were viewed as more useful and beneficial than negative results. But families who did not get positive results were eligible for follow-up that might include additional sequencing if warranted.

These studies clearly show that genomic sequencing can be done safely in the NICU, leading to improved communication between families and their healthcare teams, says Dimmock. These results underscore the importance of rapid test results in changing care.

The patients clinicians, typically a neonatologist or pediatric intensivist, were the ones who reported test results to the parents. Dimmock noted that at the start of the study, some physicians who were not specialists in genetics reported anxiety about whether they would be able to do this. This concern was later discussed with many of the othersites in the overall study as well.

Rady has been pioneering the use of rapid diagnostic sequencing in pediatric ICUs. In apilotstudy funded by theState of California, their teamdemonstrated that a rapid sequencing of critically illbabies enrolled in Medi-Cal produced better health outcomes and reduced suffering for the infants while decreasing the cost of their care. The study, named ProjectBaby Bear,helpeddoctors identifythe exact cause of rare, genetic diseasesin an average of three days, instead of the four to six weeks required for standard genetic testing.

The hospital has also published research in Genomic Medicine (2018) showing that whole-genome sequencing and whole-exome sequencing of children with suspected genetic diseases are more useful for establishing a diagnosis than chromosomal microarrays (CMAs), which are the traditional testing method for such cases.

Other stakeholders seem to be watching the progress of programs like Radys as well. In March of this year, Blue Shield of California became the first health plan in the United States to cover rapid and ultra-rapid Whole Genome Sequencing for critically ill babies and children in intensive care with unexplained medical conditions.

The biggest barriers to this type of testing becoming widespread, Dimmock adds, is getting institutional approval for the procedure and reimbursement. The Rady researchers will be looking at their data further with respect to costs to help address that latter challenge.

The rest is here:
First Line Sequencing Seen as a Win for Both Parents and Doctors of Infants in ICU - Clinical OMICs News

Breast Cancer Predictive Genetic Testing Market 2026 Industry Trends, Size, Growth Insight, Share, Emerging Technologies, Share, Competitive,…

The recent published research report sheds light on critical aspects of the global Breast Cancer Predictive Genetic Testing market such as vendor landscape, competitive strategies, market drivers and challenges along with the regional analysis. The report helps the readers to draw a suitable conclusion and clearly understand the current (Ongoing COVID-19) and future scenario and trends of global Breast Cancer Predictive Genetic Testing market. The research study comes out as a compilation of useful guidelines for players to understand and define their strategies more efficiently in order to keep themselves ahead of their competitors. The report profiles leading companies of the global Breast Cancer Predictive Genetic Testing market along with the emerging new ventures who are creating an impact on the global market with their latest innovations and technologies.

The report consists of trends that are anticipated to impact the growth of the Breast Cancer Predictive Genetic Testing market during the forecast period between 2020 and 2026. Evaluation of these trends is included in the report, along with their product innovations.

Ask For Free Sample Copy of This Research Report:https://www.readmarketresearch.com/sample-request/33675-world-breast-cancer-predictive-genetic-testing-market

This Report covers the manufacturers data including shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size and volume.

Global Breast Cancer Predictive Genetic Testing Market by Companies:Key companies listed in the report are:Roche, Thermo Fisher Scientific, PerkinElmer, Quest Diagnostics, Myriad Genetics, Iverson Genetics, Cancer Genetics, OncoCyte Corporation, NeoGenomics, Invitae

Global Breast Cancer Predictive Genetic Testing Market by Product:The key segment by type in the report includesHigh Penetrant Genes, Intermediate Penetrant Genes, Low Penetrant Genes

Global Breast Cancer Predictive Genetic Testing Market by Application:The report provides both market size and share information for following application from 2016-2026. The key applications of the market are:Hospitals, Clinics and Others

Read detail report:https://www.readmarketresearch.com/industry-report/33675/world-breast-cancer-predictive-genetic-testing-market

Table of ContentsGlobal Breast Cancer Predictive Genetic Testing Market Research Report 2020-2026, by Manufacturers, Regions, Types and Applications

1 Breast Cancer Predictive Genetic Testing Market Overview1.1 Introduction1.2 Scope1.3 Assumptions1.4 Players Covered1.5 Market Analysis By Type1.5.1 Global Breast Cancer Predictive Genetic Testing Market Size Growth Rate By Type (2020-2026)1.5.2 1.6 Market By Application1.6.1 Global Breast Cancer Predictive Genetic Testing Market Share By Application (2020-2026)1.6.2 Application I1.6.3 Application Ii1.6.4 1.7 Study Objectives1.8 Years

2 Executive Summary

3 Breast Cancer Predictive Genetic Testing Market Analysis by Type (Historic 2016-2026)3.1 Global Breast Cancer Predictive Genetic Testing Market Size Analysis (USD Million) 2016-20263.1.1 Type I3.1.2 Type Ii3.1.3 Type Iii3.2 Global Breast Cancer Predictive Genetic Testing Market Share Analysis by Type (%) 2016-2026

4 Breast Cancer Predictive Genetic Testing Market Analysis By Application (Historic 2016-2026)4.1 Global Breast Cancer Predictive Genetic Testing Market Size Analysis (USD Million) 2016-2026

5 Breast Cancer Predictive Genetic Testing Market Analysis By Regions (Historic 2016-2026)5.1 Global Breast Cancer Predictive Genetic Testing Market Size Analysis (USD Million) 2016-20265.1.1 Breast Cancer Predictive Genetic Testing Market Share By Regions (2016-2026)5.1.2 United States5.1.3 Europe5.1.4 China5.1.5 Japan5.1.6 India5.1.7 Rest Of The World

6 Key Companies Analysis/Company Profile

Continued..

Buy the Up-to-date Full Report @www.readmarketresearch.com/checkout?buynow=33675-world-breast-cancer-predictive-genetic-testing-market

Objectives of global Breast Cancer Predictive Genetic Testing Market Study: To define, describe, and analyse the global Breast Cancer Predictive Genetic Testing market based on product type, Application, and Region To forecast and analyse global Breast Cancer Predictive Genetic Testing market size (in terms of value and volume) and submarkets in 5 regions namely, APAC, Europe, North America, Central & South America, and the Middle East & Africa To forecast and analyse global Breast Cancer Predictive Genetic Testing market at country-level for each region To strategically analyse each submarket with respect to individual growth trends and their contribution to the global Breast Cancer Predictive Genetic Testing market To analyse opportunities in the market for stakeholders by identifying high growth segments of the global Breast Cancer Predictive Genetic Testing market To identify trends and factors driving or inhibiting the growth of the market and submarkets To analyse competitive developments, such as expansions and new product launches, in the global Breast Cancer Predictive Genetic Testing market To strategically profile key market players and comprehensively analyze their growth strategies

Ask for the discount:https://www.readmarketresearch.com/enquiry-before-purchase/33675-world-breast-cancer-predictive-genetic-testing-market*Get Upto $1000 Flat Discount on All License Type.

About UsWe at Read offers wide range of business services including but not limited to Market Research, Syndicate and Custom Research, Company Research, Business Consulting, Audit & Risk, Communications, Finance, Information Technology, Legal & Compliance, Human Resources and Sales.

Contact:Read Market ResearchDev Dixit (Sales Manager)B-51 CMPDI, Korba, ChhattisgarhPhone: +1 646 583 1932Email:[emailprotected]Web:https://www.readmarketresearch.comFollow Us on:LinkedIN

Read the original here:
Breast Cancer Predictive Genetic Testing Market 2026 Industry Trends, Size, Growth Insight, Share, Emerging Technologies, Share, Competitive,...

Genetic Testing Services Market Analysis With Key Players, Applications, Trends And Forecasts To 2026 – Zenit News

Syndicate Market Research published a new 110+ pages industry research, Industry Perspective, Comprehensive Analysis, and Forecast, 20202026in its database that focuses onGenetic Testing Services Marketand delivers in-depth market analysis and future prospects of Global Genetic Testing Services Market. This market report delivers the clean elaborated structure of the Genetic Testing Services Market comprising each and every business-related information of the market at a global level. The complete range of information related to the global Genetic Testing Services Market is obtained through various sources and this obtained bulk of the information is arranged, processed, and represented by a group of specialists through the application of different methodological techniques and analytical tools such as SWOT analysis to generate a whole set of trade-based study regarding the global Genetic Testing Services Market.

Request Sample is Available Genetic Testing Services Market Report @https://www.syndicatemarketresearch.com/sample/genetic-testing-services-market.html

The global Genetic Testing Services Market supports market-linked various associations, industries, vendors, firms, and organizations by offering a broad stage revealing opportunities time-to-time to rise higher in the market. Some of the chief contenders including pre-established businesses and newly-emerging firms are contending with one another for global trade expansion in terms of production, supply, demand, income, and after-sales services.

The Major Market Players Are:Hoffmann-La Roche Ltd, Illumina, 23andMe, Ambry Genetics, Genomic Health, Eurofins Scientific, LabCorp, CENTOGENE, Quest Diagnostics Incorporated, NeoGenomics Laboratories

Promising Regions & Countries Mentioned In The Genetic Testing Services Market Report:

North America (United States, Canada) Europe (UK, Germany, France) Asia-Pacific (Japan, China, India) Latin America (Argentina, Brazil) The Middle East & Africa

By the product type, the market is primarily split intoPredictive Testing, Carrier Testing, Prenatal and Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, Others

By the application/end users, this report covers the following segmentsLarge National Laboratories, Small Laboratories, Specialty Laboratories, Diagnostic Laboratories, Others

The global Genetic Testing Services Market report presents the detailed extensive study regarding the market in an efficient way by dividing the whole market into different segments [Product, Applications, End-Users, and Major Regions] on the basis of type and form of product offered by the industries, product processing methods and techniques, end-user applications, and others. Not only this, but the market study also categorizes the market based on the regions [Latin America, North America, Asia Pacific, Middle & East Africa, and Europe]. The report also comprises the market growth forecast information calculated by the professional on the basis of previous information about the market and its related industries as well as the current trends followed by the market. The report also provides the markets CAGR forecast for the specific period of the upcoming time.

The report also highlights the various key factors as well as administrative guidelines that may impact the market in both ways, either direct or indirect. The global Genetic Testing Services Market report is embedded with several charts, figures, graphs, and diagrams to make it better understandable for the clients.

Following are significant Table of Content of Genetic Testing Services Market Report:

Industry Overview of Genetic Testing Services Market. Manufacturing Cost Structure Analysis of Genetic Testing Services Market market. Technical Data and Manufacturing Plants Analysis of Genetic Testing Services Market. Capacity, Production, and Revenue Analysis. Price, Cost, Gross, and Gross Margin Analysis of Genetic Testing Services Market by Regions, Types, and Manufacturers. Consumption Volume, Consumption Value, and Sale Price Analysis of Genetic Testing Services Market industry by Regions, Types, and Applications. Supply, Import, Export, and Consumption Analysis of Genetic Testing Services Market Market. Major Manufacturers Analysis of Genetic Testing Services Market industry. Marketing Trader or Distributor Analysis of Genetic Testing Services Market. Industry Chain Analysis of Genetic Testing Services Market. Development Trend Analysis of Genetic Testing Services Market Market. New Project Investment Feasibility Analysis of Genetic Testing Services Market. A conclusion of the Genetic Testing Services Market Industry.

Inquire more about this report @https://www.syndicatemarketresearch.com/inquiry/genetic-testing-services-market

Purposes Behind Buying Genetic Testing Services Market Report:-

This report gives stick direct investigation toward changing focused elements. It gives a forward-looking viewpoint on changed elements producing or restricting market development. It gives a five-year assessment surveyed based on how the market is anticipated to develop. It helps in understanding the essential part sections and their prospect. It gives stick point investigation of changing rivalry elements and keeps you in front of contenders. It helps in settling on educated business choices by having complete bits of knowledge of the market and by making a top to bottom investigation of market fragments.

Thanks for reading this article; you can also get individual chapter wise section or region wise report versions like North America, Europe, or Asia.

Contact Us:Email ID:[emailprotected]

Continued here:
Genetic Testing Services Market Analysis With Key Players, Applications, Trends And Forecasts To 2026 - Zenit News

Newborn and Prenatal Genetic Testing Market to Make Great Impact in near Future by 2027 – KYT24

This report studies the Newborn and Prenatal Genetic Testing to get Covid-19 marketplace with Many details of the industry such as the market size, market standing, marketplace trends and prediction, the report also provides brief advice of their opponents as well as the particular growth opportunities with key market drivers. Locate the complete Newborn and Prenatal Genetic Testing to get Covid-19 market evaluation segmented by firms, area, type and software in the document.

New sellers from the marketplace are facing tough competition from Established foreign vendors as they fight with technological inventions, quality and reliability problems. The report will answer questions regarding the present market changes and the reach of competition, opportunity cost and much more.

Request Sample Report @ https://beathanreports.com/request-for-sample-report/7533

The report discusses the various Kinds of options for While the areas considered in the range of the report include North America, Europe, and assorted others. The analysis also highlights on how climbing digital security dangers is altering the industry situation.

Development policies and strategies are discussed along with Manufacturing processes and cost structures will also be examined. This report also claims import/export consumption, supply and demand Statistics, price, cost, earnings and gross earnings.

This report concentrates on the international Newborn and Prenatal Genetic Testing for Covid-19 Status, future prediction, growth opportunity, key marketplace and players.

The following players are covered in this report:

Perkin Elmer

Verinata Health

Sequenom, Inc.

Agilent Technologies, Inc.

Bio-Rad Laboratories, Inc.

Natera, Inc.

Illumina, Inc.

Ariosa Diagnostics

BGI

CapitalBio MedLab

The Newborn and Prenatal Genetic Testing for Covid-19 marketplace is a comprehensive record Which supplies a meticulous summary of the market share, size, trends, demand, product evaluation, program analysis, regional perspective, competitive strategies, predictions, and strategies affecting the Newborn and Prenatal Genetic Testing for Covid-19 Industry. The report contains a thorough analysis of this marketplace competitive landscape, with the assistance of comprehensive business profiles, SWOT analysis, project feasibility analysis, and a lot of other specifics about the essential companies working on the marketplace.

Request Discount About This Report @ https://beathanreports.com/discount-request-on-report/7533

The analysis aims Covid-19 in global sector.

Breakdown Data by Type

PCR

FISH

aCGH

NIPT

MSS

Newborn and Prenatal Genetic Testing Breakdown Data by Application

Hospital

Clinic

Others

Based on regional and country-level analysis, the Newborn and Prenatal Genetic Testing market has been segmented as follows:

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Nordic

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia-Pacific

Latin America

Mexico

Brazil

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of Middle East & Africa

In the competitive analysis section of the report, leading as well as prominent players of the global Newborn and Prenatal Genetic Testing market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.

The following players are covered in this report:

Perkin Elmer

Verinata Health

Sequenom, Inc.

Agilent Technologies, Inc.

Bio-Rad Laboratories, Inc.

Natera, Inc.

Illumina, Inc.

Ariosa Diagnostics

BGI

CapitalBio MedLab

The Newborn and Prenatal Genetic Testing for Covid-19 market study report entirely Covers the very important data of their capacity, manufacturing, value, cost/profit, supply/demand import/export, further separated by country and company, and from application/type for the best possible upgraded information representation from the statistics, tables, pie graph, and charts. These data representations give predictive information concerning the potential estimations for persuasive market development. The detailed and in depth understanding concerning our publishers makes us from the box in the event of market evaluation.

Key questions Answered within this report

Request For Customization About This Report @ https://beathanreports.com/request-for-customization/7533

Table of Contents

Chapter 1: Global Newborn and Prenatal Genetic Testing for Covid-19 Market Overview

Chapter 2: Newborn and Prenatal Genetic Testing for Covid-19 Market Data Analysis

Chapter 3: Newborn and Prenatal Genetic Testing for Covid-19 Technical Data Analysis

Chapter 4: Newborn and Prenatal Genetic Testing for Covid-19 Government Policy and News

Chapter 5: Global Newborn and Prenatal Genetic Testing for Covid-19 Market Manufacturing Process and Cost Structure

Chapter 6: Newborn and Prenatal Genetic Testing for Covid-19 Productions Supply Sales Demand Market Status and Forecast

Chapter 7: Newborn and Prenatal Genetic Testing for Covid-19 Key Manufacturers

Chapter 8: Up and Down Stream Industry Analysis

Chapter 9: Marketing Strategy -Newborn and Prenatal Genetic Testing for Covid-19 Analysis

Chapter 10: Newborn and Prenatal Genetic Testing for Covid-19 Development Trend Analysis

Chapter 11: Global Newborn and Prenatal Genetic Testing for Covid-19 Market New Project Investment Feasibility Analysis

Contact Us

Beathan Report,

4004 W Lake Sammamish,

Pkway B9 Redmond,

WA 98052 United States.

Tel: +44 115 888 3028

Web: http://www.beathanreports.com

About Us

At Beathan Report, we understand that the research we provide is only as good as the outcome it inspires. These reports are generated by well-renowned publishers on the basis of the data acquired from an extensive research and credible business statistics. Thats why we are proud to provide the widest range of research products, multilingual 24/7 customer support and dedicated custom research services to deliver the insights you need to achieve your goals. Take a look at few of our aspects that makes Beathan Report an asset to your business.

Read the rest here:
Newborn and Prenatal Genetic Testing Market to Make Great Impact in near Future by 2027 - KYT24

Largest Study To-Date Focused on Undiagnosed Genetic Disease Patients Reveals That Bionano’s Optical Genome Mapping Technology Can Diagnose…

SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication of a study led by scientists and clinicians from the Institute for Human Genetics and the Benioff Childrens Hospital at the University of California, San Francisco (UCSF) that evaluated the ability of Bionanos optical genome mapping technology and another genome analysis method to diagnose children with genetic conditions who previously went undiagnosed by the standard of care methods alone. Of the 50 children in the study, the optical genome mapping results were sufficient to definitively diagnose 6 patients (or 12%) and, for another 10 patients (or 20%), the Bionano data revealed candidate pathogenic variants. Upon further analysis, it is expected that an additional 3 patients could be diagnosed with the Bionano data, bringing the total of definitively diagnosed patients to 9 (or 18%).

Erik Holmlin, Ph.D., CEO of Bionano Genomics commented, Increasing the number of patients who receive a definitive molecular diagnosis is the driving force behind much of the development of new diagnostic technologies. Every major change in medical guidelines connected to introducing novel methods has been driven by the ability of new methods to diagnose more patients than the previously existing standard of care. This study by the UCSF team shows that Bionanos optical genome mapping can potentially bring another such leap to the clinic by diagnosing many more patients than what existing chromosomal microarray (CMA) and whole exome sequencing (WES) can. Several studies released this year have shown that Saphyr can detect all clinically relevant variants identified by karyotyping, microarray and FISH in both leukemias and genetic disease cases. This UCSF study now shows in the largest cohort analyzed to date that Bionanos optical genome mapping diagnoses more patients than the traditional methods. We believe the increase in diagnosis over conventional methods can be a significant factor in Saphyr gaining widespread adoption as a clinical tool for genetic disease diagnosis and next-generation cytogenomics.

As described in the publication, the UCSF team performed full genome analysis by combining optical genome mapping with Bionano technology and linked-read sequencing on 50 undiagnosed patients with a variety of rare genetic diseases and their parents to determine if this full genome analysis method could help solve cases that had not been diagnosed with previous testing. Of the 50 cases, 42 were previously analyzed by CMA, the first tier medical test for genetic disease cases, and 23 had previously been analyzed with commercial trio whole exome sequencing, and no pathogenic or likely pathogenic variants were identified by these methods.

Bionanos optical genome mapping technology identified a number of pathogenic variants unidentified by CMA and undetectable by WES, including duplications and deletions that were too small to be identified by CMA, or occurred in regions of the genome not typically covered by CMA or WES. Of the additional 7 patients with variations considered to be candidates for pathogenic variants, the findings included deletions, duplications, and inversions. Before concluding that these variants are sufficient to diagnose the patients, further analysis is required since these variants had not previously been reported in patients with similar disease.

The publication is available at: https://www.medrxiv.org/content/10.1101/2020.10.22.20216531v1A recording of the webinar is available at: https://bionanogenomics.com/webinars/optical-mapping-in-rare-genetic-disease-diagnosis/

About Bionano GenomicsBionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionanos Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. For more information, visitwww.bionanogenomics.com or http://www.lineagen.com.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, expect, plan, anticipate, estimate, intend and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the contribution of Bionanos technology to the diagnosis of more genetic disease patients when compared to traditional standard of care methods; the capabilities of Bionanos technology in comparison to other genome analysis technologies; our expectations regarding the adoption of Saphyr as a clinical tool for genetic disease diagnosis and next-generation cytogenomics; and Bionanos strategic plans. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; the loss of key members of management and our commercial team; and the risks and uncertainties associated withour business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACTSCompany Contact:Erik Holmlin, CEOBionano Genomics, Inc.+1 (858) 888-7610eholmlin@bionanogenomics.com

Investor Relations Contact:Ashley R. RobinsonLifeSci Advisors, LLC+1 (617) 430-7577arr@lifesciadvisors.com

Media Contact:Darren Opland, PhDLifeSci Communications+1 (617) 733-7668darren@lifescicomms.com

See more here:
Largest Study To-Date Focused on Undiagnosed Genetic Disease Patients Reveals That Bionano's Optical Genome Mapping Technology Can Diagnose...

Double-Hit and Triple-Hit Lymphoma: How Do They Affect Treatment? – SurvivorNet

Using Your Cancer's Genes to Plan Treatment

When youre first diagnosed with non-Hodgkin lymphoma, your doctor will need to learn more about your tumor. Tests done on a sample of the cancer removed during a biopsy can reveal how your cancer is likely to behave whether it will grow quickly or slowly.

We do extensive molecular and genetic testing to identify certain genetic markers that can predict a high-risk behavior of the tumor, specifically gene rearrangements, Dr. Suchitra Sundaram, medical oncologist at Roswell Park Cancer Center, tells SurvivorNet.

What your doctor learns through these tests can help predict what treatments are likely to work most effectively against your cancer, and what your outcome could be.

Your biopsy sample will go to a laboratory, where a specialist called a pathologist will evaluate its size, shape, and other characteristics under a microscope including its genetic makeup. A few tests look at the cancer cells chromosomes the threads that carry the cells genetic information:

Normally, cells have 23 pairs of chromosomes. Lymphoma cells have changes in their chromosomes for example, too few or too many chromosomes, or areas where genes swap places on chromosomes. These changes can help your doctor learn what type of lymphoma you have, and how it is likely to behave.

Depending upon the number of adverse gene rearrangements identified, some of these patients can be classified into double-hit or triple-hit lymphoma, Dr. Sundaram explains.

Double-hit lymphoma is a type of lymphoma in which there are switches in two genes: MYC or BCL2. Triple-hit lymphoma has changes in three genes: MYC, BCL2, and BCL6. These genes help to control cell growth and death. Changes to them can help the cancer cells survive.

Both double- and triple-hit lymphomas are similar to diffuse large B-cell lymphoma or Burkitt lymphoma. Theyre more aggressive cancers, and people who have them typically have worse overall survival as compared to patients without these gene rearrangements, Dr. Sundaram says.

These lymphomas are more likely to start in people over age 60. They cause swollen lymph nodes, as well as whats known as B symptoms fevers, night sweats, and unexplained weight loss.

Because these cancers are so aggressive, often people are diagnosed when their cancer is already at a late stage. In a small percentage of people with double- and triple-hit lymphoma, the cancer spreads to the brain and spinal cord.

Finding gene swaps is crucial for treatment planning, because some of these patients with double-hit or triple-hit lymphoma may not have the same response to standard chemoimmunotherapy approaches compared to patients without these gene rearrangements, Dr. Sundaram tells SurvivorNet.

Double- and triple-hit lymphomas can be hard to treat. Because they are pretty rare and they havent been well-studied, there is no standard combination of chemotherapy and immunotherapy used to treat them. And, these cancers are more likely to relapse after treatment than more common types of B-cell lymphoma.

Dr. Sundaram says its important for people with double-hit and triple-hit lymphoma to enroll in clinical trials of new drugs combined with chemotherapy and immunotherapy. Taking part in one of these studies could give you access to a new treatment or combination of treatments thats not yet available to the public, and which might work better against your cancer.

Ask the doctor who treats your lymphoma if an appropriate clinical trial is available in your area. If not, your doctor may give you the standard combination of chemotherapy and the monoclonal antibody drug, rituximab (Rituxan), known as R-CHOP. Or, you could get a more intensive combination of chemotherapy and immunotherapy drugs. Your doctor might also prescribe treatment to prevent the cancer from spreading to your brain and spinal cord.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Suchitra Sundaram is a medical oncologist at Roswell Park Cancer Center in Buffalo, New York, as well as an assistant professor of medicine. Her specialties include non-Hodgkin lymphoma, Hodgkin lymphoma, chronic lymphocytic leukemia, and multiple myeloma. Read More

We do extensive molecular and genetic testing to identify certain genetic markers that can predict a high-risk behavior of the tumor, specifically gene rearrangements, Dr. Suchitra Sundaram, medical oncologist at Roswell Park Cancer Center, tells SurvivorNet.

Your biopsy sample will go to a laboratory, where a specialist called a pathologist will evaluate its size, shape, and other characteristics under a microscope including its genetic makeup. A few tests look at the cancer cells chromosomes the threads that carry the cells genetic information:

Normally, cells have 23 pairs of chromosomes. Lymphoma cells have changes in their chromosomes for example, too few or too many chromosomes, or areas where genes swap places on chromosomes. These changes can help your doctor learn what type of lymphoma you have, and how it is likely to behave.

Depending upon the number of adverse gene rearrangements identified, some of these patients can be classified into double-hit or triple-hit lymphoma, Dr. Sundaram explains.

Double-hit lymphoma is a type of lymphoma in which there are switches in two genes: MYC or BCL2. Triple-hit lymphoma has changes in three genes: MYC, BCL2, and BCL6. These genes help to control cell growth and death. Changes to them can help the cancer cells survive.

Both double- and triple-hit lymphomas are similar to diffuse large B-cell lymphoma or Burkitt lymphoma. Theyre more aggressive cancers, and people who have them typically have worse overall survival as compared to patients without these gene rearrangements, Dr. Sundaram says.

These lymphomas are more likely to start in people over age 60. They cause swollen lymph nodes, as well as whats known as B symptoms fevers, night sweats, and unexplained weight loss.

Because these cancers are so aggressive, often people are diagnosed when their cancer is already at a late stage. In a small percentage of people with double- and triple-hit lymphoma, the cancer spreads to the brain and spinal cord.

Finding gene swaps is crucial for treatment planning, because some of these patients with double-hit or triple-hit lymphoma may not have the same response to standard chemoimmunotherapy approaches compared to patients without these gene rearrangements, Dr. Sundaram tells SurvivorNet.

Double- and triple-hit lymphomas can be hard to treat. Because they are pretty rare and they havent been well-studied, there is no standard combination of chemotherapy and immunotherapy used to treat them. And, these cancers are more likely to relapse after treatment than more common types of B-cell lymphoma.

Dr. Sundaram says its important for people with double-hit and triple-hit lymphoma to enroll in clinical trials of new drugs combined with chemotherapy and immunotherapy. Taking part in one of these studies could give you access to a new treatment or combination of treatments thats not yet available to the public, and which might work better against your cancer.

Ask the doctor who treats your lymphoma if an appropriate clinical trial is available in your area. If not, your doctor may give you the standard combination of chemotherapy and the monoclonal antibody drug, rituximab (Rituxan), known as R-CHOP. Or, you could get a more intensive combination of chemotherapy and immunotherapy drugs. Your doctor might also prescribe treatment to prevent the cancer from spreading to your brain and spinal cord.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Suchitra Sundaram is a medical oncologist at Roswell Park Cancer Center in Buffalo, New York, as well as an assistant professor of medicine. Her specialties include non-Hodgkin lymphoma, Hodgkin lymphoma, chronic lymphocytic leukemia, and multiple myeloma. Read More

Read the rest here:
Double-Hit and Triple-Hit Lymphoma: How Do They Affect Treatment? - SurvivorNet

Preimplantation Genetic Testing Market with Future Prospects, Key Player SWOT Analysis and Forecast To 2027 – TechnoWeekly

Preimplantation Genetic Testing Market Size And Forecast

A comprehensive overview of the Preimplantation Genetic Testing Market is recently added by Market Research Intellect to its humongous database. Furthermore, the Preimplantation Genetic Testing Market report has been aggregated by collecting informative data of various dynamics such as market drivers, restraints, and opportunities. Furthermore, this innovative report makes use of SWOT, PESTLE, and Porters Five Forces analyses to get a closer outlook on the Preimplantation Genetic Testing Market. Furthermore, the Preimplantation Genetic Testing Market report offers a detailed analysis of the latest industry developments and trending factors in the market that are influencing the market growth. Furthermore, this statistical market research repository examines and estimates the Preimplantation Genetic Testing Market at the global and regional levels. The study covers the impact of various drivers and manacles on the Preimplantation Genetic Testing Market growth opportunities over the forecast period.

Impact of Covid-19 :

During the first quarter of 2020, different global economies were badly impacted by a viral outbreak of COVID-19. This viral outbreak of the Covid-19 was later recognized as a global pandemic by the World Health Organization (WHO). COVID-19 spread in different global countries, affecting a large number of people in a short timeframe. The outburst of COVID-19 adversely hit different global economies in the world. The stringent regulations imposed by several governments, including complete lockdown and quarantine methodologies to fight against COVID-19, resulted in a massive impact on various business sectors. We at Market Research Intellect offer an informative report on the Preimplantation Genetic Testing Market which helps in making strategic decisions over the forecast period.

Competitive Landscape:

The degree of competition among leading global companies has been elaborated by examining various leading key players operating across the global regions An expert team of research analysts sheds light on various attributes such as -global market competition, market share, latest industry developments, innovative product launches, partnerships, mergers or acquisitions by leading companies in the Preimplantation Genetic Testing Market. The leading manufacturers have been analyzed by using research methodologies for getting insight views on global competition.

Following key players have been profiled with the help of proven research methodologies:

The Preimplantation Genetic Testing Market has been examined into different global market segments such as type, applications and global geographies. Each and every global market segment has been studied to get informative insights into various global regions.

Preimplantation Genetic Testing Market Segmentation:

Preimplantation Genetic Testing Market Segment by Type:

Preimplantation Genetic Testing Market Segment by Application:

Preimplantation Genetic Testing Market Segment by Global Presence:

North America Latin America Middle East Asia-Pacific Africa Europe

The report has been aggregated by using a couple of research methodologies such as primary and secondary research techniques. It helps in collecting informative pieces of professional information for deriving effective insights into the market. This informative report helps in making well informed and strategic decisions throughout the forecast period.

Key questions answered through this analytical market research report include:

What are the latest trends, new patterns and technological advancements in the Preimplantation Genetic Testing Market? Which factors are influencing the Preimplantation Genetic Testing Market over the forecast period? What are the global challenges, threats and risks in the Preimplantation Genetic Testing Market? Which factors are propelling and restraining the Preimplantation Genetic Testing Market? What are the demanding global regions of the Preimplantation Genetic Testing Market? What will be the global market size over the coming future? What are the different effective business strategies followed by global companies?

If you have any custom requirements, please let us know and we will offer you the customized report as per your requirements.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Website https://www.marketresearchintellect.com/

Visit link:
Preimplantation Genetic Testing Market with Future Prospects, Key Player SWOT Analysis and Forecast To 2027 - TechnoWeekly

Preimplantation Genetic Testing Market Report Analysis With Industry Share Published by Leading Research Firm – TechnoWeekly

Global Preimplantation Genetic Testing Market: An Overview

The preimplantation genetic testing is an increasingly go-to option for identifying genetic birth effects in children. The technique relies on the use of vitro fertilization before pregnancy. The technique is highly recommended in clinical practices especially in cases wherein both parents have a genetic defect. The tests are performed on an embryo to determine various genetic associations or factors. The PGD or preimplantation genetic diagnosis is the medium to avail this test.

Read Report Overview https://www.transparencymarketresearch.com/preimplantation-genetic-testing-market.html

On the other hand, PGS or presumed genetic screening refers to techniques are applied for the screening of genetically sound parents. The technique is used to screen aneuploidy. The growing demand for genetically testing and rising knowledge of genetics, thanks to big data and AI technology is a promising driver for growth of the preimplantation genetic testing market.

Preimplantation Genetic Testing Market: Notable Developments

In 2018, twin girls in China were conceived using embryos that were specifically designed with the method of gene altering. In 2019, a 74 year Indian women gave birth to first-time twins. It is estimated that nearly 12% of the overall couples are infertile. Additionally, thanks to rising financial stress, and compatibility issues, women tend to conceive a far later in lifecycle. The growth of couples opting for reproductive technologies in Denmark stands at near 7% of all couples. The new technologies made available due to preimplantation genetic testing is expected to witness robust future as economies of scale drive down costs.

Request for Analysis of COVID-19 Impact on Preimplantation Genetic Testing Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=70167

HelpCureHD, an organization has helped 24 families with Huntingtons disease to conceive healthy. The family-supported organization paid for the treatment of 24 families who were diagnosed with huntingtons disease. This is important to take note of as reproduction remains a key family concern and is likely to drive growth from charities. However, the costs of preimplantation genetic testing remain high and pose a major barrier to growth.

Preimplantation Genetic Testing Market: Drivers and Restraints

The rising advent of medical knowledge and growth of technologically advanced genetic devices are expected to result in considerable growth for the preimplantation genetic testing market. Additionally, positive response from several regulatory authorities to genetic testing and possible opportunities for conceving healthier children are expected to be major opportunities. Additionally, more tech companies are also expected to invest in testing.

Recently, Facebook announced its desire to pay women more to conceive later as many women opted out of their jobs to take care of their families. The growing need for women to seek a balance between family and career, and growing tendency towards opting for family are expected to drive investment from the tech sector wherein salaries are extremely high and replacing labor can be far more costly.

Pre Book Preimplantation Genetic Testing Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=70167&ltype=S

Preimplantation Genetic Testing Market: Geographical Analysis

The preimplantation genetic testing market is expected to witness major growth in North America region. The growing choice of women towards conceiving later, growing reliance on technology to identify pre-birth conditions, and expected cutting down costs due to scales of economy are expected to drive major growth in region. Additionally, the preimplantation genetic testing market is expected to drive considerable growth in Asia Pacific region. The region is home to a rising disposable income, and growing access to healthcare. Additionally, large investment in big data and Artificial Intelligence technology by countries like Japan and China are expected to remain major drivers for growth.

More Trending Reports by Transparency Market Research

Serological Testing Market: https://www.biospace.com/article/serological-testing-market-hepatitis-segment-is-anticipated-to-expand-at-the-highest-cagr-during-the-forecast-period/

Disposable Oxygen Masks Market: https://www.biospace.com/article/disposable-oxygen-masks-market-ault-disposable-oxygen-masks-segment-to-offer-attractive-opportunities/

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

Read more:
Preimplantation Genetic Testing Market Report Analysis With Industry Share Published by Leading Research Firm - TechnoWeekly

Shady Grove Fertility’s (SGF) Partnership with Previvor and Model, Allyn Rose, Sheds Light on How IVF Can Help Reduce the Genetic Risk of Breast…

Allyn Rose poses with SGF's Dr. Kate Devine.

WASHINGTON (PRWEB) October 29, 2020

Shady Grove Fertility (SGF) honors National Breast Cancer Awareness Month in partnership with breast cancer advocate and Previvor Founder, Allyn Rose, by expanding awareness of advancements in fertility treatment. Through preimplantation genetic testing, couples can have peace of mind knowing that genetic mutations that can lead to inherited conditions and disease have a strong chance of ending with their generation.

The month of October serves as an important reminder that this year, an estimated 700,000 people in the U.S. will be diagnosed with breast cancer, of which, up to 10 percent of cases are linked to an inherited gene mutation.

In the last letter that my mother wrote to me before her passing from metastatic breast cancer at age 50, she warned me of my familys predisposition to cancer and rare diseases, encouraging me to undergo in vitro fertilization (IVF) treatment to eliminate this disease, says Rose, a former Miss USA and Miss America contestant, model, and the recipient of the 21st Annual Congress on Womens Healths Advocacy Award and a Breast Cancer Summit Lifetime Achievement Award. Her forethought, 16 years prior to today, was the catalyst for me to take charge of my reproductive health.

SGF is the largest fertility center in the U.S. with 37 locations and home to more than 85,000 babies born. SGF offers patients the opportunity to screen for over 280 recessive gene mutations, including diseases such as cystic fibrosis, Tay-Sachs disease, and spinal muscular atrophy. In addition, patients at risk for dominant gene mutations, such as breast cancer or inherited forms of colon cancer, can have individualized testing for these diseases.

Couples with known genetic diseases can turn to in vitro fertilization (IVF) with preimplantation genetic testing for monogenic/single gene defects (PGT-M) to reduce the risk of passing that mutation onto their child(ren).

In 2019, a partnership between SGF and Rose blossomed to educate patients of these interventions and the availability of fertility preservation prior to any cancer treatment by sharing Roses personal journey. Not only did a 16-year-old Rose cope with the loss of her mother from breast cancer at a young age, she also experienced the passing of her grandmother and great aunt to the same fate.

It was from these events that Rose made nationwide headlines with her decision to undergo a preventative (prophylactic) double (bilateral) mastectomy to prolong her life, despite not being a carrier for a genetic breast mutation. Roses personal experience soon became a platform that encouraged other women to seek preventive healthcare, including her #SelfExamGram social media movement that reminds women to perform routine self-breast exams.

I knew that my journey of preventive healthcare didnt end with my mastectomy, says Rose. Im also a carrier of another very rare X-linked genetic mutation called Wiskott-Aldrich syndrome. This genetic mutation would affect 50% of my male children and 50% of my female children would be carriers of the disease like me. If I was taking steps to prolong my own life, it only made sense that I would do the same for my future children.

Last October, Rose started her IVF journey with Kate Devine, M.D., at SGFs Washington, D.C. - K Street location, opting to undergo PGT-M to reduce the risk of having a child with an inherited condition. Rose is documenting her journey to motherhood with Dr. Devine and SGF in hopes that it will lift the veil of the unknown associated with infertility treatment while serving as a reminder to women to be their own advocates.

The thing I love about SGF, and what I think makes them stand out, is that a large number of their staff have undergone fertility treatments themselves, says Rose. I really appreciated that because I felt like they actually understood what I was going through and when they told me that I would be okay they meant it.

This past July, ironically on the 16th anniversary of the passing of Roses mother, she announced she was pregnant with her first child after completing 10 months of IVF treatment with SGF.

Allyns story is a powerful reminder to women everywhere that theyre not alone, says Dr. Devine. IVF with PGT-M is a safe and reliable means of fertility treatment for women who want to reduce risk of known genetic mutations in their children. Im so happy that Allyn and her husband will soon welcome a baby whos free of Wiskott-Aldrich gene mutations.

While Rose is cancer-free, SGF has a specially trained team that works specifically with people with cancer to ensure the fertility preservation process before cancer treatment can be expedited in order that cancer treatment can quickly begin. The oncofertility team at SGF helps to guide patients through each step of the treatment process, from finding ways to afford treatment to the actual medical procedure.

If you would like to learn more about SGFs oncofertility treatment options or to schedule an appointment, please call the New Patient Center at 1-888-761-1967 or complete this brief online form.

About Shady Grove Fertility (SGF)SGF is a leading fertility and IVF center of excellence with more than 85,000 babies born and 5,000+ 5-star patient reviews. With 37 locations throughout FL, GA, MD, NY, PA, VA, D.C., and Santiago, Chile, we offer patients virtual physician consults, deliver individualized care, accept most insurance plans, and make treatment affordable through innovative financial options, including 100% refund guarantees. More physicians refer their patients to SGF than any other center. Call 1-888-761-1967 or visit ShadyGroveFertility.com.

Share article on social media or email:

Read the rest here:
Shady Grove Fertility's (SGF) Partnership with Previvor and Model, Allyn Rose, Sheds Light on How IVF Can Help Reduce the Genetic Risk of Breast...

Heath woman delivers knockout to breast cancer – The Newark Advocate

Buy Photo

Shanay Nye of Heath, who is celebrating her one-year anniversary of being a breast cancer survivor, shows off a blanket full of family photos that friend Megan Harter got her for last Christmas.(Photo: Dave Weidig/The Advocate)

HEATH - Shanay Nye celebrated a special anniversary last week.

It was not the 15th wedding anniversary with her husband, Bryan Nye. It will be in the future, but that anniversary would not be possibleif not for what led up to the other one.

On Oct. 21, during National Breast Cancer Awareness Month, the Heath woman celebrated her one-year anniversary of being free from the disease. If not for early diagnosis, and local gynecologist Dr. Janae Davis, Nye and family might not have been able to celebrate.

After leukemia treatments: Massive treehouse fulfills Newark boy's wish

She wants to share her story, not only as a way of urging women to get mammograms even at a young age, but to show there is plenty of hope once diagnosed.

Nye is 39, but at age 37, she was diagnosed in April of 2019 with Invasive Ductal Carcinoma/HER2 positive breast cancer. "I never thought it would happen to me," she said. "I did genetic testing, and I was not a carrier of cancer genes, plus no one in my family had it."

In 2018, Dr. Davis said she felt something, when she performed a mammogram on Nye at age 36. "It turned out to be nothing, a benign cyst," said Nye, who is a transition specialist for the Licking County Board of Developmental Disabilities. "But that got me put on a list for another test the next year. She (Dr. Davis) is amazing. She saved my life."

Shanay Nye of Heath is shown during one of the six chemotherapy sessions she received for breast cancer last year at the Zangmeister Cancer Center.(Photo: Courtesy of Shanay Nye)

In February of 2019, a week before her appointment, Nye performed a self check. "I only did them occasionally, but I felt something on my left side," she recalled. "I told them, and they did a diagnostic, instead of just the normal services," Nye said. "They also did an ultrasound. Then, Dr. Davis said I should go in for a biopsy."

Dr. Davis called Nye at work, and informed her that her lymph node had tested positive for cancer. "I was in shock," she said. "What do I now?" Her immediate thoughts went to Bryan, on active duty with the National Guard who works at the Armory in Newark, and her children: Colton Crawmer, 17, a senior at Lakewood, 10-year-old Bryce who is in fifth grade at Heath's Stevenson Elementary, and 6-year-old Lexi who is a first grader at Heath's Garfield Elementary.

Friendly rivalry for good: Johnstown and Northridge students support local food pantry

She started out with six rounds of chemotherapy at Zangmeister Cancer Center in Columbus. "My oncologist, Dr. Emily Whitman, said it would help slow the rate of re-occurrence," Nye said. "I had to take five days off work for each treatment. Days three and four were usually the worst."

Fortunately, Nye had a lot of support from a large family (she has three brothers and three sisters plus her parents), friends, and co-workers at Licking County Board of Developmental Disabilities. Ashley Bryan, LCBDD service coordinator, raised money for Shanay through the purchase of T-shirts and selling breast cancer bracelets. The shirts said "Who Says Girls Can't Fight?" on the front, and "Shanay's Tribe" on the back.

"I also organized a meal train during the weeks that she had chemo, so that others were able to help by providing a meal for her and her family," Bryan said. "That way, she could rest."

The Licking County Board of Developmental Disabilities showed support for transition specialist Shanay Nye (front, center) during her battle against breast cancer, by wearing shirts and bracelets organized by LCBDD service coordinator Ashley Bryan.(Photo: Courtesy of Licking County Board of Developmental Disabilities)

Her last chemo treatment was Sept. 25 of last year. Nye was a candidate for a lumpectomy, performed by Mount Carmel surgeon Dr. Kristine Slam, and it was found that the chemo had taken out the cancer mass. So tissue around the mass, and the lymph node were removed. Then Nye had to undergo 30 rounds of radiation treatment after surgery. "They were being proactive, and making sure it (the cancer) didn't come back," she said.

On Oct. 21, 2019, it was determined that she had come back completely from the cancer, and was classified as an NED (No Evidence from Disease). She continued her year-long Herceptin treatment up until June 4 of this year. "I just had my six-month mammogram last week, and it came back clear," Nye said. "Now, I get one every year instead of six months. I still will see my oncologist and surgeon every three months for five years. If I make it to five years, it's a good indication that it is not going to come back."

20 Under 40: Young leaders motivated by community response during difficult year

Throughout her ordeal, Nye shared photos and videos on her "Shanay's Tribe" Facebook page, documenting her treatments and the side effects. She continues to share her story as much as possible, doing a "story slam" with the National Breast Cancer Foundation, and also a spot for the Licking County Health Department's SASS (Screening And Survivor Support) breast cancer group.

Nye has learned a lot, and wants to educate other women.

"Things couldn't have gone any better, and I am blessed to get through it as well as I did," she said. "Because a lot of women struggle with it. Self checks are not done enough, especially among younger women. Mammograms should be started a lot earlier. I met so many other younger women, even in their 20's. The youngest was diagnosed at 18."

Nye could not have gotten through it without all the support she received. Megan Harter, another service coordinator at LCBDD, got her a fleece blanket for Christmas that features various pictures of she and her family.

"She sure has been through a lot, with being so young, and I know we are all so happy to see her win this fight," Bryan said.

dweidig@gannett.com

740-973-4503

Twitter: @noz75

Read or Share this story: https://www.newarkadvocate.com/story/news/local/2020/10/29/national-breast-cancer-awareness-month-heath-woman/6066460002/

Continued here:
Heath woman delivers knockout to breast cancer - The Newark Advocate

Global Genetic Testing Services Professional Survey 2020 by Manufacturers, Regions, Types and Applications, Forecast to 2026 – The Think Curiouser

COVID-19 Outbreak-Global Genetic Testing Services Market Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020 is latest research study released by SMR Market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support. The influencing Factors of growth and regulations with respect to the usage of the information, availability of highly reliable products in the market, and increase in operational efficiency of COVID-19 Outbreak. The study provides information on market trends and development, drivers, capacities, technologies, and on the changing dynamics of COVID-19 Outbreak.

As per study key and emerging players of this market are

Hoffmann-La Roche Ltd, Illumina, 23andMe, Ambry Genetics, Genomic Health, Eurofins Scientific, LabCorp, CENTOGENE, Quest Diagnostics Incorporated, NeoGenomics Laboratories

The recent study on the Genetic Testing Services market offers a detailed scrutiny of the key growth catalysts, restraints, and opportunities that are deemed critical to the overall progression of the market over the forecast duration. Additionally, the document offers an in-depth analysis of the various industry segments to help readers in understanding the top revenue prospects of this business vertical.

As per trusted projections, the Genetic Testing Services market is slated accumulate notable returns, registering a CAGR of XX% over 2020-2025.

Request Sample Copy of this [emailprotected]https://www.syndicatemarketresearch.com/sample/genetic-testing-services-market.html

Key pointers of the Genetic Testing Services market report:

Regional bifurcation:

North America (United States, Canada and Mexico) Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia) Europe (Germany, France, UK, Russia and Italy) South America (Brazil, Argentina, Colombia)

Strategic Points Covered in Table of Content of Global Genetic Testing Services Market:

Chapter 1:Exclusive Summary the basic information of the Market.

Chapter 2:Introduction, market driving force product Objective of Study and Research Scope of the market.

Chapter 3:Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the Market

Chapter 4:Displaying the by Type, End User and Region/Country 2020-2025

Chapter 5:Presenting the Global Genetic Testing Services Market Factor Analysis, Post COVID Impact Analysis,Porters Five Forces,Value Chain, PESTEL analysis, Market Entropy,Trademark Analysis.

Chapter 6:Evaluating the leading manufacturers of the Global Genetic Testing Services market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7:To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions (2020-2025)

Chapter 8 & 9:Displaying the Appendix, Methodology and Data Source

Finally, Global Genetic Testing Services Market is a valuable source of guidance for individuals and companies in their decision framework.

Request Customization on This [emailprotected]https://www.syndicatemarketresearch.com/inquiry/genetic-testing-services-market

Table of Contents

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Genetic Testing Services Market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the Global Genetic Testing Services Market are discussed.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Report Overview:It includes major players of the global Genetic Testing Services Market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Get More Informationhttps://www.syndicatemarketresearch.com/market-analysis/genetic-testing-services-market.html

About us:

Setting a strong foot in the industry with all planned and diplomatic way is surely not a cinch. You need loads of research, analysis, consider several factors, and above all, give your valuable time to the entire process. This is where Syndicate Market Research kicks in as a support system for our clients. Our reports targets high gain profitable markets in The Middle East & Africa, USA, Europe, and Asia Pacific covering industries like IT and Machinery & Equipment, Automotive, Food & Beverage, Telecommunications, Chemicals and Materials, Electronics & Semiconductor, Healthcare & Pharma, Energy & Mining, Manufacturing & Construction, etc.

Syndicate Market Research244 Fifth Avenue, Suite N202New York, 10001, United StatesEmail ID:[emailprotected]Website:https://www.syndicatemarketresearch.com/Blog:Syndicate Market Research Blog

View post:
Global Genetic Testing Services Professional Survey 2020 by Manufacturers, Regions, Types and Applications, Forecast to 2026 - The Think Curiouser

Genetic Testing Market Share -2023, Business Overview, Product Types, Developments of Key Players, Market Trends and Drivers – Aerospace Journal

Global Genetic Testing Market report provides a detailed analysis of market overview and trends, key segments, business strategies, developments of key players, the future outlook of the market. This research report gives comprehensive knowledge and valuable insights about the Genetic Testing market. The report contains an in-depth analysis of the market size, growth, opportunities, product types, and services. The market is expected to grow at a different CAGR value during the forecast period of 2018-2023.

The report offers an overview of revenue, market share, demand, restraints, and supply of data during the projected year. These factors are becoming increasingly important in the present scenario.

Market Dynamics :

> Drivers Increasing Emphasis on Early Disease Detection and Prevention Growing Demand for Personalized Medicine Increasing Application of Genetic Testing in Oncology

> Restraints High Costs of Genetic Testing Social and Ethical Implications of Genetic Testing

> Opportunities

> Key Challenges

Regional Analysis:

This Genetic Testing report analysis segmented by geography, market share and revenues, market size, technologies, growth rate and forecast period of the following regions are including:

US, Canada, Mexico, UK, France, Germany, Italy, Spain, Rest of Europe, India, China, Japan, Australia, South Korea, Rest of APAC, GCC, South Africa, Rest of MEA, Brazil, Argentina, Rest of South Africa

The Genetic Testing market contains industry challenges, business expansion plans, competitive landscape, key development, and accurate country-wise volume analysis and region-wise market size analysis of the global market. This detailed assessment of the market will help the company increase efficiency.

Inquire or Share Your Questions If Any Before the Purchasing This Report https://www.absolutereports.com/enquiry/pre-order-enquiry/13100469

Key Developments in the Market::> September 2017: Myriad Launched riskScore to enhance the hereditary cancer test myRisk. riskScore determines the risk of women to get breast cancer by analyzing their genome.> July 2017: Admera Health Partners collaborates with Helix to Launch Genetic Tests to Assess the Risk of Inherited High Cholesterol, Sudden Cardiac Death, and Inherited Diabetes

Key Reasons to Purchase this Report:

Purchase this Report (Price 4250 USD for a Single-User License) https://www.absolutereports.com/checkout/13100469

Detailed TOC of Global Genetic Testing Market Growth, Trends, Challenges and Forecast (2018 2023)

1 Genetic Testing Market Introduction

1.1 Study Deliverables

1.2 General Study Assumptions

2 Research Methodology

2.1 Introduction

2.2 Analysis Methodology

2.3 Study Phases

2.4 Econometric Modelling

3 Executive Summary

4 Genetic Testing Market Overview and Trends

4.1 Introduction

4.2 Genetic Testing Market Trends

4.3 Porters Five Force Framework

Continued

For Detailed TOC https://www.absolutereports.com/TOC/13100469#TOC

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Rail Seats Market Report Size 2020-2026, Segment by Application, Types and Revenue, Business Growth and Strategy and Challenges

Global Titanate Ceramics Market 2020-2026 Industry Growth, Top Key Players Trends, Sales and Revenue, Business strategy Analysis and Distributors

Gigabit Ethernet Switches Market Growth and Demand, Product Overview, Company Profiles and Recent Business Development, Forecast to 2020-2026

Global EV (Electric Vehicle) Charging Adapter Market Size 2020-2026, Top Leading Key Regions, Global Growth Trends, Market Scope and Size, Industry Growth Strategy

Global Citrus Bioflavonoids Market 2020-2026 Industry Growth, Top Key Players Trends, Sales and Revenue, Business strategy Analysis and Distributors

Ammonium Sulfate (CAS 7783-20-2) Market Growth and Demand, Product Overview, Company Profiles and Recent Business Development, Forecast to 2020-2026

Photomicro Sensors Market Status and Outlook 2020 by Region, Top manufactures, Industry Trends, Market Drivers and Distributors, Forecast Period of 2020-2026

Smart Augmented Reality Glasses Market 2020 by Business Strategy, Development History, Types, Applications and Trends, Distributors, Top Regions, Different Manufacture

Follow this link:
Genetic Testing Market Share -2023, Business Overview, Product Types, Developments of Key Players, Market Trends and Drivers - Aerospace Journal

Preimplantation Genetic Testing to Discern Steadfast Expansion During 2017 to 2022 – The Think Curiouser

The Most Recent study on the Preimplantation Genetic Testing Market Research provides a profound comprehension of the various market dynamics like trends, drivers, the challenges, and opportunities. The report further elaborates on the micro and macro-economic elements that are predicted to shape the increase of the Preimplantation Genetic Testing market throughout the forecast period (2019-2029).

The introduced study elucidates the crucial indicators of Market growth which comes with a thorough analysis of this value chain, CAGR development, and Porters Five Forces Analysis. This data may enable readers to understand the quantitative growth parameters of this international industry that is Preimplantation Genetic Testing .

Analytical Insights Included from the Preimplantation Genetic Testing Market Report

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=292

Preimplantation Genetic Testing Market Segmentation Assessment

The increase prospects of this market in various Regions are studied in the report together with details like the regulatory framework, political, and financial outlook of each region.

Competition Tracking

The report also profiles companies operating in the preimplantation genetic testing market, which include Agilent Technologies Inc., Abbott Laboratories, CooperSurgical Inc., Oxford Gene Technology IP, Illumina, Inc., Thermo Fisher Scientific, Inc., PerkinElmer, Inc., Genea Limited, Natera, Inc., Rubicon Genomics, Inc., and CombiMatrix Corporation.

Note: The insights mentioned here are of the respective analysts, and do not reflect the position of Fact.MR

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=292

The Report intends to eliminate the subsequent doubts regarding the Preimplantation Genetic Testing market:

Reasons To Choose Fact.MR:

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=292

Read more here:
Preimplantation Genetic Testing to Discern Steadfast Expansion During 2017 to 2022 - The Think Curiouser

Preimplantation Genetic Testing Market Report, History and Forecast 2020-2027, Data Breakdown by Manufacturers, Key Regions, Types and Application -…

The Global Preimplantation Genetic Testing Market report offers key insights into the worldwide Preimplantation Genetic Testing market. It presents a holistic overview of the market, with an in-depth summary of the markets leading players. The report is inclusive of indispensable information related to the leading competitors in this business sector and carefully analyzes the micro- and macro-economic market trends. The latest report specializes in studying primary and secondary market drivers, market share, the leading market segments, and comprehensive geographical analysis. Vital information about the key market players and their key business strategies, such as mergers & acquisitions, collaborations, technological innovation, and trending business policies, is one of the key components of the report.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2244

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

Illumina Inc.; Thermo Fisher Scientific, Inc.; Natera, Inc.; Bioarray S.L.; Good Start Genetics, Inc.; Laboratory Corporation of America Holdings; California Pacific Medical Center; Quest Diagnostics Incorporated; CooperSurgical, Inc.; Genea Limited; IGENOMIX; Reproductive Genetic Innovations, Reproductive Health Science Ltd.

Furthermore, our market analysts have drawn focus to the significant impact of the COVID-19 pandemic on the global Preimplantation Genetic Testing market and its key segments and sub-segments. The grave aftereffects of the pandemic on the global economy, and subsequently, on this particular business sphere, have been enumerated in this section of the report. The report considers the key market-influencing parameters, delivering a detailed future impact assessment. The Preimplantation Genetic Testing market has been devastated by the pandemic, which has culminated in drastic changes to the market dynamics and demand trends.

In market segmentation by types of Preimplantation Genetic Testing, the report covers-

In market segmentation by applications of the Preimplantation Genetic Testing, the report covers the following uses-

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2244

Moreover, the research report thoroughly examines the size, share, and market volume of the Preimplantation Genetic Testing industry in the historical years to forecast the same valuations over the forecast duration. It offers exhaustive SWOT analysis, Porters Five Forces analysis, feasibility analysis, and investment return analysis of the Preimplantation Genetic Testing market, assessed using certain effective analytical tools. The report also provides strategic recommendations to market entrants to help them navigate around the entry-level barriers.

The global Preimplantation Genetic Testing market is geographically categorized into:

The following timeline is considered for market estimation:

Historical Years: 2017-2018

Base Year: 2019

Estimated Year: 2020

Forecast Years: 2020-2027

Key Coverage of the Report:

To read more about the report, visit@ https://www.reportsanddata.com/report-detail/preimplantation-genetic-testing-market

Thank you for reading our report. For further information or queries regarding the report, please get in touch with us. Our team will make sure your report is tailored according to your requirements.

About Us:

Our in-house experts assist our clients with advice based on their proficiency in the market that helps them in creating a compendious database for the clients. Our team offers expert insights to clients to guide them through their business ventures. We put in rigorous efforts to keep our clientele satisfied and focus on fulfilling their demands to make sure that the end-product is what they desire. We excel in diverse fields of the market and with our services extending to competitive analysis, research and development analysis, and demand estimation among others, we can help you invest your funds in the most beneficial areas for research and development. You can rely on us to provide every significant detail you might need in your efforts to make your business flourish.

Contact Us:

John Watson

Head of Business Development

Reports and Data|Web: http://www.reportsanddata.com

Direct Line:+1-212-710-1370

E-mail: [emailprotected]

See more here:
Preimplantation Genetic Testing Market Report, History and Forecast 2020-2027, Data Breakdown by Manufacturers, Key Regions, Types and Application -...

Archives